High palmitic acid oil compositions and their uses

By modifying non-genetic engineering methods for microalgae cells, oils with high palmitic acid content and low linoleic acid content were screened out, solving the problems of declining biodiversity and high costs in palm oil production, providing a sustainable oil alternative, simplifying the production process and reducing costs.

CN123125318APending Publication Date: 2026-11-17CHECKERSPORT CO
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202580025983.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2024-02-05
Filing Date
2025-02-05
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

The existing palm oil production process suffers from biodiversity loss, and the preparation process of high palmitic acid oils is complex and costly, making it difficult to provide sustainable alternatives to palm oil.

Method used

Microalgal cells were improved through non-genetic engineering. Microalgal cells were mutated using ultraviolet light and 4-nitroquinoline-1-oxide, and combined with physical conditions and chemical compound treatments to screen for oils with high palmitic acid content and low linoleic acid content. High palmitic acid oils were then produced using a simplified biotransformation method.

Benefits of technology

It provides an oil alternative with high palmitic acid content, simplifies the production process, reduces costs, avoids the impact on biodiversity in tropical regions, meets non-GMO and organic labeling standards, and has commercial and regulatory advantages.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123125318A_ABST
    Figure CN123125318A_ABST
Patent Text Reader

Abstract

This document provides algal oil compositions, including algal oil compositions containing high levels of palmitic acid and high levels of palmitic-oleic-palmitic acid (POP). This document also provides methods for producing said compositions and their application in personal care and home care products.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] Cross-references to related applications

[0002] This international application claims priority to U.S. Provisional Patent Application No. 63 / 549,843, filed February 5, 2024, the entire contents of which are incorporated herein by reference.

[0003] By referencing and incorporating into the sequence list

[0004] This application includes a sequence listing XML file submitted electronically in XML file format, the entire contents of which are incorporated herein by reference. The sequence listing XML file was created on February 3, 2025, is named 009919_00098_WO_SL.xml, and has a size of 142,039 bytes. Background Technology

[0005] Oil-producing microorganisms can convert carbon substrates into lipids (including triglycerides (TAG) or lipids) and accumulate these lipids within their cells. Some microorganisms can accumulate lipids up to 89% of their cell dry weight. Therefore, oil-producing microorganisms (including microalgae, bacteria, fungi, and yeast) are ideal sources for bio-based lipid production. Through genetic and non-genetic modification techniques, lipids with specific fatty acid profiles can be produced.

[0006] Oils rich in palmitic acid have significant value in numerous industries, including food, personal care, home care, cosmetics, and biofuels. However, the base oils providing high palmitic acid content are derived from oil palms (…). Elaeis guineensis Palm oil is a semi-solid product of palm oil production. Because palm oil is semi-solid at room temperature, it is typically fractionated into a fluid fraction (palm extract oil) and a solid fraction (palm stearin). It is well known that palm extract oil contains higher levels of oleic and linoleic acids compared to palm oil. The demand for palm oil and the development of this industry have led to a significant decline in biodiversity in tropical palm-growing regions. Therefore, there is an urgent need to develop sustainable sources of palm oil.

[0007] By incorporating references

[0008] All publications, patents and patent applications mentioned in this specification are incorporated herein by reference to the same extent that each publication, patent or patent application is expressly and individually indicated to be incorporated by reference. Summary of the Invention

[0009] In some aspects, this disclosure provides an oil containing a TAG component, wherein the TAG component has a fatty acid content of at least 30% or more palmitic acid (C16:0).

[0010] In some aspects, this disclosure provides an oil obtained by non-genetic engineering means, comprising a TAG component having a fatty acid content of 30% or more palmitic acid (C16:0), 45% or more oleic acid (C18:1), and 8% or less linoleic acid (C18:2).

[0011] In some aspects, this disclosure provides an oil derived from microalgae cells comprising a TAG component, wherein the TAG component has a fatty acid content comprising 30% or more of (C16:0) acid, and wherein the TAG component has a low linoleic acid content.

[0012] In some respects, this disclosure provides an oil derived from microalgae cells, wherein the oil provides an alternative to palm oil-derived liquid oil.

[0013] In some aspects, this disclosure provides an oil derived from microalgal cells comprising a TAG component, wherein the TAG component contains at least 30% C16:0 fatty acids and at least 40% C18:1 fatty acids, and the oil is produced by modifying microalgal cells with classical strains.

[0014] In some aspects, this disclosure provides an oil derived from microalgae cells comprising a TAG component, wherein the TAG component has a fatty acid content comprising 30% or more of C16:0 fatty acids, and wherein the oil further comprises less than 1% of tripalmitoylglycerol.

[0015] In some aspects, this disclosure provides an oil containing a TAG component having a fatty acid content of at least 30% C16:0 fatty acids, less than about 1% diacylglycerols, and less than about 1% monoacylglycerols.

[0016] In some respects, the oils and fats disclosed herein also contain sterols, such as ergosterol.

[0017] In some aspects, this disclosure provides an oil obtained by non-genetic engineering means, comprising a TAG component having a fatty acid content of 49% or more palmitic acid (C16:0), about 36% or less oleic acid (C18:1), and 8% or less linoleic acid (C18:2).

[0018] In some aspects, this disclosure provides an oil obtained by non-genetic engineering means, which comprises a TAG component having a POP (palmitoic acid-oleic acid-palmitoic acid) TAG comprising 45% or more of all TAG types, while a PPP (tripalmitoylglycerol) TAG comprising less than 2.7%.

[0019] In some respects, this disclosure provides a method for targeting mulberry-shaped non-green algae (… Prototheca moriformis A combined screening method involves mutagenesis using activators, including ultraviolet light (254 nm) and 4-nitroquinoline-1-oxide (4-NQO); followed by multiple rounds of growth in a lipid-producing medium at a maximum temperature of approximately 38°C; and then a brief incubation (maximum approximately 4 minutes) at a near-lethal temperature (maximum approximately 68°C). After incubation at the lethal temperature, cells are allowed to recover in a low-glucose (i.e., medium containing a maximum of 5 g / L) growth medium for approximately 1 to 5 days (e.g., a maximum of approximately 3 days), after which the cells are plated on plates containing growth medium. Clones are then picked and cultured in lipid-producing medium, and the lipids (oils) produced are screened for fatty acid profiles. The screening method for fatty acid profiles is as follows: fatty acid methyl esters (FAME) are generated, and FAME is detected using gas chromatography-flame ionization detection (GC / FID). The triacylglycerol (TAG) composition of the lipids is then analyzed using liquid chromatography-time-of-flight mass spectrometry (LC / TOF-MS) equipped with an atmospheric pressure chemical ionization (APCI) source. Using this method, those skilled in the art can obtain microalgal cells capable of producing lipids with the desired TAG composition.

[0020] In some respects, this disclosure provides a method for producing valuable structured fats via the biotransformation of sugars, wherein the fats have a composition or components similar to those of palm intermediate fractions, but without the need for capital equipment, deep fractionation, and high-loss processes.

[0021] In one embodiment, an isolated microalgal cell, such as *Non-green algae*, is provided. Prototheca sp. The cells, obtained by modifying classic microalgae cells, wherein the microalgae cells produce an oil characterized by comprising: (a) at least 17% of 1,3-dipalmitoyl-2-oleoylglycerol (POP) of the TAG component, or at least 23%, or at least 29%, or at least 32%, or at least 35%, or at least 45%; and (b) less than 0.3%, or less than about 0.6%, or less than about 1.0%, or less than at least 1.2%, or less than about 1.5%, or less than about 2.7% of the tripalmitoylglycerol (PPP) of the TAG component.

[0022] In another embodiment, the isolated microalgal cells have a POP content of at least about 45%, or at least about 50%, or at least about 55%, or at least about 60%, and the PPP content is less than about 2.7% of the TAG component.

[0023] In another embodiment, the microalgal oil comprising the TAG component has the following TAG components: (a) at least 17% of 1,3-dipalmitoyl-2-oleoylglycerol (POP) content in the TAG component, or at least 23%, or at least 29%, or at least 32%, or at least 35%, or at least 45%; and (b) less than 0.3% of tripalmitoylglycerol (PPP) content in the TAG component, or less than about 0.6%, or less than about 1.0%, or less than at least 1.2%, or less than about 1.5%, or less than about 2.7% of the TAG; and wherein the microalgal oil is derived from a microalgae (Aureobasidium) obtained through modification of classical strains. Prototheca ) produced by cells.

[0024] In one respect, the microalgal lipids produced by the microalgal cells described herein originate from cells without the introduction of exogenous nucleic acids. In another respect, the oil-producing microalgal cells obtained through the classical methods described herein can be further engineered using exogenous nucleic acids; these exogenous nucleic acids are not naturally present in the parental microalgal cells that produced the strain.

[0025] In another embodiment, the microalgae oil has a TAG component comprising: (a) at least 45% of 1,3-dipalmitoyl-2-oleoylglycerol (POP); and (b) less than about 2.7% of the TAG of tripalmitoylglycerol (PPP). Alternatively, a contemplated microalgae oil may have: (a) at least 35% of POP and less than about 1.5% of PPP; or (b) at least 45% of POP and less than about 2.7% of PPP. The microalgae oil described above and herein may further comprise at least about 30% of C16:0 fatty acids, or at least about 35% of C16:0 fatty acids, or at least about 40% of C16:0 fatty acids, or at least about 45% of C16:0 fatty acids, or at least about 50% of C16:0 fatty acids.

[0026] This disclosure also envisions a method for obtaining microalgal cells capable of producing the lipids of any one of claims 4 to 8, the method comprising the steps of: (a) culturing the microalgal cells in a nutrient medium or lipid-producing medium at about 28°C to about 38°C, while mutagenizing the microalgal cells with at least one or more known agents that promote DNA excision repair errors (e.g., ultraviolet light (e.g., 254 nm), 4-nitroquinoline-1-oxide (4-NQO), methyl methanesulfonate (MMS), Ni, Ar, or polycyclic aromatic hydrocarbons); and (b) enriching the mutagenized microalgal cells by exposing the mutagenized microalgal cells to physical conditions (e.g., elevated temperatures of about 50°C to about 68°C, or by using density fractionation according to a sucrose or Percoll gradient to separate specific subpopulations according to density) or chemical compounds (e.g., herbicides, fungicides, lipid biosynthesis inhibitors such as tebutam or cofenstrole). (c) Growing mutagenized and enriched microalgal cells in a lipid-producing medium; and (d) harvesting microalgal oil from the microalgal cells and detecting the microalgal oil using FAME analysis and triacylglycerol (TAG) analysis to determine the components of the screened microalgal cells; wherein the TAG components of the screened microalgal cells comprise: (e) at least 17% of 1,3-dipalmitoyl-2-oleoylglycerol (POP) content, or at least 23%, or at least 29%, or at least 32%, or at least 35%, or at least 45% of the TAG component; and (f) less than 0.3%, or less than about 0.6%, or less than about 1.0%, or less than at least 1.2%, or less than about 1.5%, or less than about 2.7% of the tripalmitoylglycerol (PPP) content of the TAG component. In a preferred embodiment, the method uses a species of *Aureobasidium* (*Aureobasidium*). Prototheca sp. )cell.

[0027] Another embodiment is a method for obtaining microalgal oil from the microalgal cells described herein, the method comprising: (a) mutagenizing cells with an active agent known to induce mutations by promoting DNA excision repair errors, said active agent including but not limited to ultraviolet light (254 nm), 4-nitroquinoline-1-oxide (4-NQO), methyl methanesulfonate (MMS), Ni, Ar, or polycyclic aromatic hydrocarbons; culturing said microalgal cells in a nutrient medium or lipid-producing medium at about 28°C to about 38°C; (b) enriching said cell population using physical conditions (e.g., elevated temperatures of about 50°C, about 60°C, or up to about 68°C, or fractionation according to a sucrose or Percoll gradient to separate specific subpopulations according to density) or chemical compounds (e.g., herbicides, fungicides, or lipid biosynthesis inhibitors such as oxychloride or chlorpyrifos); (c) spreading the aforementioned mutagenized and enriched population onto a solid nutrient medium; (d) growing said individuals in a lipid-producing medium; (e) harvesting microalgal cells from said lipid-producing medium; (f) Microalgal lipids were obtained from cultured microalgal cells and detected by FAME and TAG analysis.

[0028] This overview introduces several concepts in a simplified form, which will be further elaborated in the specific implementation. This overview is not intended to identify key or essential features of the claimed subject matter, nor is it intended to limit the claimed subject matter in any way. Attached Figure Description

[0029] Novel features of the TAG components of microalgal lipids, microalgal lipids and the microalgae that produce them, and the method for obtaining said unpurified lipids are set forth in the appended claims. The features and advantages of the methods, compositions, and components can be better understood with reference to the following detailed description and accompanying drawings, which illustrate exemplary embodiments in which the principles of the compositions, components, and methods are applied; wherein the drawings are: Figure 1A and 1B This shows UTEX 1533 (SEQ ID NO:30, named Wickham Green Algae-Free). Prototheca wickerhamii Comparison of plasmid 23S rDNA sequences between the strain and the mulberry-shaped non-green algae strain (denoted as UTEX 1435, SEQ ID NO:31) Figure 2A and 2B A flowchart is shown illustrating the mutagenic trait selection, high-throughput, and automated screening steps in the improvement process described in this paper.

[0030] Figure 3This disclosure provides an overview of the workflows and strategies used in the improvement of classic strains for constructing mutants derived from UTEX 1533.

[0031] Figure 4 The TIC chromatograms of triacylglycerols extracted from classically modified mutant isolates (ac / CHK100 mutant isolates 1-3) derived from the classically modified basic strain CHK100(d) are shown.

[0032] Figure 5 for Figure 4 Mass spectrum of POP / PPO triacylglycerol present in mutant isolate (a) / CHK100 mutant isolate 1.

[0033] Figure 6 for Figure 4 Mass spectrum of POP / PPO triacylglycerol present in mutant isolate (b) / CHK100 mutant isolate 2.

[0034] Figure 7 for Figure 4 Mass spectrum of POP / PPO triacylglycerol present in mutant isolate (c) / CHK100 mutant isolate 3.

[0035] Figure 8 for Figure 4 Mass spectrum of POP / PPO triacylglycerols present in the parent strain CHK100.

[0036] Figure 9 This is the mass spectrum of POP / PPO triacylglycerols in red palm oil.

[0037] Figure 10 The mass spectrum is for the analytical standard of 1,3-palmitoyl-2-oleic acid glyceride.

[0038] Figure 11 The mass spectrum is for the analytical standard of 1,2-palmitoyl-3-oleic acid glyceride.

[0039] Figure 12 This is a comparison diagram of the triglyceride spectra of some of the high palmitic acid strains disclosed herein and red palm oil.

[0040] Figure 13 for Figure 4 Comparison of triglyceride spectra of mutant isolate (b) and red palm oil.

[0041] Figure 14 This is a comparison chart of the levels of palmitic acid (C16:0) and unsaturated fatty acids (the sum of C18:1 and C18:2 fatty acids) in the novel oil and palm oil of this disclosure.

[0042] Figure 15 A comparison diagram of the TAG spectra of oils produced by the high palmitic acid algae strain of this disclosure and the TAG spectra of palm oil is shown.

[0043] Figure 16 The FAME (fatty acid methyl ester) spectra of the mutant BLK08 F04, derived from algal strain 268U, are shown after lipid production culture at 28℃ and 32℃.

[0044] Figure 17 The TAG spectra of the mutant BLK08 F04, derived from algal strain 268U, were shown during lipid production culture at 28℃ and 32℃, with the PPO and POP positional isomers marked.

[0045] Figure 18 The comparison of the positional isomers of PPO and POP and the PPP level in the intermediate fractions of red palm oil and palm oil with the classic improved algal strain of this disclosure is shown. Detailed Implementation

[0046] This article provides a microalgae oil composition with high palmitic acid content, high POP TAG content, and low PPP content, as well as its preparation method, formulation, and application. Microalgae oil with the aforementioned high palmitic acid and POP TAG content ratio and low PPP content can be directly used as a readily available alternative source for fractions obtained from palm oil, which involve numerous fractionation steps and take many days to obtain the desired intermediate fraction.

[0047] The main palm species cultivated globally is the oil palm (Palm palm) Elaeis guineensis Palm oil comes from palm fruit or its various cultivars and varieties. One source of palm oil is the palm fruit, which consists of the fleshy outer mesocarp that encloses the hard kernel or endocarp. The oil from the palm fruit differs significantly from the oil from the hard palm kernel (known as "palm kernel oil" ("PKO")). PKO is characterized by high levels of C12:0 fatty acids (lauric acid, >45%) and C14:0 (myristic acid, >15%), and relatively low levels of C16:0 palmitic acid (8%) and C18:1 oleic acid (15%). Palm oil derived from the palm fruit contains almost no C12:0 and C14:0 fatty acids and is primarily composed of palmitic acid (40-46%), oleic acid (37-45%), and some C18:2 fatty acids (linoleic acid, 8-12%).

[0048] Palm oil can be used directly "as is" in cooking and other applications (including personal care), but a significant portion of commercially available palm oil requires fractionation to obtain more valuable components. (Jin et al., "Characteristics of palm mid-fractions produced from different fractionation paths and their potential uses,") Int. J. Food Prop 21:58-69, 2018).

[0049] The first fractionation of refined palm oil (called the dry fractionation process because it does not use solvents) yields two fractions: palm oil fraction and palm stearin fraction. The palm oil fraction is a fluid at room temperature and is rich in oleic and linoleic fatty acids; the palm stearin fraction is a solid at room temperature and is highly rich in palmitic acid esters (50-60%).

[0050] Palm oil can be further fractionated by dry separation to obtain "Palm Intermediate Grade A" ("PMF-A") component. During the separation process, the palm oil is cooled to approximately 16°C, with the cooling rate depending on the specific producer and their process.

[0051] The temperature is then further reduced to 12-13°C and held at this temperature for a period of time to allow the solid PMF-A fraction to crystallize further. The PMF-A fraction is rich in palmitic acid esters, especially POP (40%). After this fractionation step, the fluid component at this low temperature is called "super oil".

[0052] Palm stearin can be further fractionated using a wet fractionation technique to prepare palm intermediate fraction B (PMF-B). This technique uses acetone (solvent:oil (wt:wt) ratio of 1:4-8), at a temperature of 17-25°C, and is maintained at the specified temperature for 8-48 hours. The solid fraction obtained from further fractionation is called "super stearin," which is rich in C18:1; while PMF-B is also rich in palmitate esters and POP fraction (45% POP).

[0053] PMF-A and PMF-B fractions can be mixed and then wet-extracted again using acetone (1:10 ratio, solvent: oil (wt:wt)). The mixture is kept at a very low temperature (e.g., about 4°C) for up to 24 hours to prepare a third fraction highly rich in POP (60-65% POP), which is called PMF-C.

[0054] The high-POP fraction obtained from palm oil by the above method has extremely high value in the confectionery industry, as it can impart the characteristic rapid melting properties of chocolate. (See BAILEY'S INDUSTRIAL OILS AND FAT PRODUCTS. 2005. 6th ed. Shahidi, Fereidoon. John Wiley and Sons, Inc., Hoboken, NJ. Vol. 4: “Edible oil and fat products: Products and Applications,” 4: 159-173) 2005.

[0055] It is not difficult for ordinary people without technical knowledge to understand that the processes involved in preparing these PMF components are very complex and costly in terms of capital (equipment costs), energy consumption (alternating cooling and heating of large amounts of oils), and hazardous chemicals (large amounts of acetone).

[0056] This article provides an embodiment of a simpler process in which fermentable sugars are converted into triacylglycerol lipids in microalgae, the POP composition of which is comparable to or better than that of PMFs obtained by the complex and costly processes currently used to prepare such substances.

[0057] Given the current supply of cocoa butter and palm oil, the use of these structured oil forms from non-GMO organisms, which are more readily available for commercial use, can reduce production costs and are less susceptible to climate change or plant viruses and diseases.

[0058] The oil and fat compositions provided herein can be produced by genetically modified or non-genetically modified microorganisms. Non-genetically modified or non-genetically engineered microorganisms, or non-GMOs, can be prepared using the methods described herein. Non-GMO microorganisms obtained by the methods described herein can also be further recombinantly modified if desired.

[0059] Both genetic and non-genetic modification techniques can be used to produce oils with specific phenotypes. While genetic engineering tends to target phenotypes induced in host oleogenous microorganisms, classical strain modification or other non-genetic engineering techniques can also be used to enhance phenotypes. Phenotypic enhancement can include: detailed presentation of specific fatty acid profiles (e.g., high palmitic acid content), carbon yield, volumetric oil accumulation (e.g., g oil / L culture medium), oil yield (e.g., g oil / L culture medium per day), and the percentage of oil to dry cell weight (DCW), serving as metrics for strain performance.

[0060] When classical strain modification techniques are used as the sole means of altering or improving strain phenotypes and properties, additional advantages can be gained from both regulatory and commercial / market perspectives. Regulatoryly, when materials are intended for chemical (non-food) applications, non-genetically engineered microorganisms are exempt from the Toxic Substances Control Act (TSCA) of agencies such as the U.S. Environmental Protection Agency (EPA), and do not require the submission of a Microbial Commercial Activity Notification (MCAN). Such exemptions also apply to other regions, such as Brazil, where these microorganisms are not required to submit strain files to the Brazilian regulatory body responsible for industrial microorganisms (the National Biosafety Technical Committee, or CTNBio, under the Ministry of Science, Technology, Innovation and Communications). Avoiding such regulations can save millions of dollars in R&D costs. From a marketing and consumer branding perspective, raw materials produced through such non-genetically engineered methods meet non-GMO and organic labeling standards, aligning with the "clean label" requirements of brands and consumers.

[0061] As used herein, the terms “classical strain improvement” or “classical strain optimization” refer to methods of randomly or semi-randomly mutagenesis of microorganisms to produce non-naturally existing strains with improved characteristics. These methods include, but are not limited to: mutagenesis of populations to produce genetic variants, random selection or screening of surviving populations to identify improved strains, and identification of improved strains by detecting products in fermentation broth. Classical strain improvement methods include: exposure to ultraviolet radiation (e.g., 254 nm), chemical mutagens (e.g., 4-nitroquinoline-1-oxide, which forms a large-volume quinolone-purine adduct while generating mutagenic superoxide radicals (see, for example, Downes, D. et al., “Characterization of the Mutagenic Spectrum of 4-Nitroquinoline 1-Oxide (4-NQO) in…”). Aspergillus nidulans by Whole Genome Sequencing,” G3, Genes, Genomics and Genetics 1-10, 2014) and / or selectors or enriching agents (see, for example, tebutam, a microtubule inhibitor and a potent inhibitor of fatty acid acyl-ACP thioesterase FATA, as described by Johnen et al., “Inhibition of acyl-ACP thioesterase as site of action of the commercial herbicides cumyluron, oxaziclomefone, bromobutide, methyldymron and tebutam,” Pest Manag Sci . 78:3620-3629, 2022).

[0062] The latter type of active agent is used after a cell population has been mutagenized, aiming to enrich or differentiate truly mutagenized cells from unmutated cells by looking for phenotypes other than those of the "wild-type" or unmutated control population. Those skilled in the art will understand that when using enrichment agents to assess the degree of difference between a mutagenized population and a control population, such control populations (or "dummy controls") are always assessed together with the mutagenized population. Selectors or enrichment agents can be physical (e.g., tolerance to extreme temperatures, buoyancy of mutagenized cells in Percoll, sucrose, or other gradients, fluorescence intensity of neutral lipid dyes (such as Nile Red or 4,4-difluoro-4-borza-3a,4a-diaza-s-indah-BODIPY), and methods for sorting high-fluorescence populations from low-fluorescence populations) or chemical (e.g., resistance of mutagenized populations to the inhibitory effects of drug reagents, herbicides, or salts). Classic strain improvement methods do not include recombinant genetic engineering methods that target one or more genomic regions, such as homologous recombination, random insertion, marker-free transformation, or CRISPR-Cas9-based techniques.

[0063] As used herein, the term "microbial lipids" refers to lipids produced or extracted from microorganisms (microbes), such as oil-producing, single-celled, eukaryotic, or prokaryotic microorganisms, including but not limited to microalgae, yeasts, bacteria, and fungi. Preferably, the microorganism is a microalga. More preferably, the microalgae is a genus of non-green algae (…). Prototheca The strain has been classically enhanced through exposure to chemical mutagens, compounds, temperature, and / or ultraviolet light.

[0064] As used herein, the terms “triacylglycerol,” “triglyceride,” or “TAG” are synonyms referring to esters formed from glycerol and three fatty acids. Typically, the fatty acid chain of a TAG is six carbon atoms or longer.

[0065] Because the glycerol backbone contains three possible sites for fatty acid esterification, it is called... sn-1 , sn-2 and sn- 3 Therefore, the number of possible TAG molecules in oils is equal to the cube of the number of types of fatty acids present in oils.

[0066] For example, an oil composed of seven different fatty acids will have 343 possible TAG molecules.

[0067] Positional isomers of TAG refer to triacylglycerol molecules that have the same fatty acid composition and molecular weight, but whose fatty acid moieties are arranged in different sequences. For example, POP in sn-1 and sn-3 Contains palmitate, in sn-2 The position contains oleic acid esters, while PPO contains... sn-1 and sn-2 Each position contains palmitic acid ester, in sn-3 The PPP contains oleic acid esters. sn-1 , sn-2 and sn-3 All positions contain palmitic acid esters and there are no positional isomers.

[0068] As used herein, the terms “TAG purity,” “molecular purity,” or “oil purity” refer to the number of molecular species that make up an oil composition, either in absolute quantities or in amounts above a certain threshold. The fewer the number of different types of TAGs in an oil, the higher its “purity.”

[0069] The properties, characterization methods, processing techniques, characteristics, and composition of fats and oils are well known in the art (see, for example, THELIPIID HANDBOOK. 2007. Gunstone, FD, Harwood, JL and Dijkstra, AJ, eds. CRC Press, Taylor and Francis Group).

[0070] As used herein, the terms "oil" or "lipid" are synonymous, referring to all the TAGs that make up oils and lipids, which constitute >98% of the molecules in lipids or oils; the remaining components consist of free fatty acids, sterols, chromosomes, metals, and phospholipids. This is roughly the composition of oils or lipids within microalgal cells before separation from the cells.

[0071] As used in this article, the term "fats" refers to oils or lipids that are solid at room temperature (approximately 20-25°C).

[0072] Microalgal lipids can be further classified according to their degree of purification and separation from other cell debris or non-lipid biomass. This separation can be achieved mechanically, i.e., by screw pressing, or chemically, i.e., by solvent extraction and bead milling, wherein the solvents include combinations of hydrocarbons (such as n-hexane, ethanol, or propane), which can be used alone or separately.

[0073] Solvents may also include aqueous solvents consisting of water and salts (such as ammonium sulfate, magnesium sulfate, sodium chloride, etc.).

[0074] Once the oil is separated from the non-lipid biomass through mechanical pressing or solvent extraction, the resulting oil is called "crude oil".

[0075] For solvent-extracted oils, the solvent-oil mixture is called a "micellae". Depending on the type of solvent, the solvent is removed and the oil is further purified by centrifugation or filter press to remove "fine particles", which are small particles of non-lipid biomass.

[0076] The composition of "crude oil" includes TAG, free fatty acids, sterols, chromosomes, metals, and phospholipids.

[0077] Crude oils can be further processed through refining. Refining aims to remove free fatty acids, which can be achieved by adding sodium hydroxide or caustic solution to generate saponins, which are then removed by centrifugation.

[0078] The refined oil undergoes further degumming treatment, including neutralizing residual alkali with citric acid and washing with water, followed by centrifugation to remove the "gum" or phospholipid fraction precipitated in the crude oil.

[0079] After refining and degumming, the oils can be decolorized by using bleaching clay to remove residual free fatty acids, metals (including Ca, PO4, Fe, Cl and K, etc.), and pigments that may affect the quality and appearance of the oils.

[0080] After refining, degumming, and decolorizing, the oils are finally purified through deodorization. The deodorization process can be carried out under vacuum conditions using steam stripping to remove volatile components and undesirable flavors from the oils. The final oil obtained is called RBD oil (i.e., refined, decolorized, and deodorized oil).

[0081] In this disclosure, the fatty acid composition or FAME profile and TAG composition or TAG profile determined from intact cells are equivalent to those determined from RBD oil for two reasons. First, the analytical methods used to determine FAME and TAG profiles (regardless of whether from whole cells or RBD oil) will result in a certain degree of purification and separation of the lipids from cell debris. Second, the lipids within cells are already highly pure substances, >98% TAG.

[0082] As used in this article, the terms “diacylglycerol,” “diglyceride,” and “DAG” refer to glycerides in which two fatty acids are esterified on the glycerol molecule.

[0083] As used in this article, the terms “monoacylglycerol,” “monoglyceride,” and “MAG” refer to glycerides in which a fatty acid is esterified on the glycerol molecule.

[0084] As used herein, the terms "fatty acid profile" or "fatty acid content" refer to the fatty acid composition of oils and fats, such as the fatty acid composition of cell-derived oils or their derivatives presented herein. The cell-derived oil derivatives presented herein include refined, decolorized, and deodorized oils and fats. Fatty acid profiles can be determined by transesterifying the oils and fats to generate fatty acid methyl esters (FAME), followed by quantification of the fatty acid types using gas chromatography (GC / FID) equipped with a flame ionization detector.

[0085] As used herein, the term "sterol profile" refers to the sterol composition of fats and oils, such as cell-derived fats or their derivatives as described herein. The cell-derived fat derivatives described herein include refined, decolorized, and deodorized fats and oils.

[0086] As used in this article, “oleic content,” “oleic acid content,” “oleate content,” and “olein content” refer to the percentage amount of oleic acid in the fatty acid profile of a substance (such as TAG oils).

[0087] As used herein, the term “C18:1 content” refers to the percentage amount of C18:1 fatty acids (e.g., oleic acid) in the fatty acid profile of a substance (e.g., microbial oils).

[0088] As used in this article, "linoleic content" and "linoleic acid content" refer to the percentage amount of linoleic acid in the fatty acid profile of a substance (such as TAG oils).

[0089] As used herein, the term “C18:2 content” refers to the percentage of C18:2 fatty acids (e.g., linoleic acid) in the fatty acid profile of a substance (e.g., microbial oils).

[0090] As used in this article, “palmitate content,” “palmitic content,” and “palmitic acid content” all refer to the percentage amount of palmitic acid in the fatty acid profile of a substance (such as microalgal oil).

[0091] As used herein, the term “C16:0 content” refers to the percentage amount of C16:0 fatty acids (e.g., palmitic acid) in the fatty acid profile of a substance (e.g., microbial oils).

[0092] As used in this article, "PPP", "tripalmitin", "tripalmitate", and "tripalmitoylglycerol" refer to triacylglycerols in which only palmitic acid or palmitate is a fatty acid on the glycerol backbone. PPP content or PPP level is usually expressed as a percentage of the TAG component.

[0093] The term "POP" or "palmitic-oleic-palmitic" can refer to the glycerol skeleton... sn-1 and sn-3 The position contains palmitic acid or palmitate, in sn-2 Triglycerides containing oleate. POP content or POP level is usually expressed as a percentage of the TAG component.

[0094] The term "PPO" or "palmitic-palmitic-oleate" can refer to the glycerol backbone. sn-1 and sn-2 The position contains palmitic acid or palmitate, in sn-3 Triglycerides containing oleate. PPO content or PPO level is usually expressed as a percentage of the TAG component.

[0095] As used herein, the terms "high palmitate" or "high palmitic" may refer to palmitic acid with a content of more than 30%, or more than 35%, more than 40%, more than 45%, more than 50%, more than 55%, or more than 60%.

[0096] As used herein, the terms “low linoleic content” or “low linoleic acid content” may refer to a total fatty acid content of less than 10%, less than 9%, less than 8%, less than 7%, less than 6%, less than 5%, less than 4%, less than 3%, less than 2%, or less than 1% linoleic acid.

[0097] As used herein, the terms “low MAG” or “low monoacylglycerol” may refer to MAG content of less than 5%, less than 4%, less than 3%, less than 2%, or less than 1% of the total lipid content of an oil.

[0098] As used herein, the terms “low DAG” or “low diacylglycerol” may refer to an oil or fat with a total lipid content of less than 5%, less than 4%, less than 3%, less than 2%, or less than 1% DAG.

[0099] As used herein, “sequence identity” refers to the percentage of identical nucleotide or amino acid residues between two compared sequences after optimal alignment. Optimal sequence alignment can be performed manually or by computer programs employing sequence alignment algorithms (e.g., Clustal W, T-coffee, COBALT, BestFit, FASTA, BLASTP, BLASTN, and TFastA). Sequence identity can be calculated by determining the number of identical positions between the two compared sequences, dividing that number by the total number of positions compared, and multiplying the result by 100; this calculation applies to DNA, RNA, and protein sequences.

[0100] As used in this article, the term “about” means ±10% of the given value.

[0101] As used herein, in classic enrichment and screening strategies, cells are cultured in a growth medium suitable for the cells used. For example, in one embodiment, non-green algae microalgae cells from a specific non-green algae strain can be cultured in a vegetative growth medium containing NaH2PO4, K2HPO4, citric acid monohydrate, MgSO4·7H2O, CuCl2·2H2O, glucose, (NH4)2SO4, and Sigma-Aldrich antifoam 204 at final concentrations of 13.6 mM, 11.4 mM, 5 mM, 0.15 mM, 40 g / L, 7.5 mM, and 0.23 g / L, respectively. The vegetative growth medium may also contain vitamins such as thiamine hydrochloride, D-pantothenic acid, biotin, cyanocobalamin, riboflavin, and pyridoxine hydrochloride at final concentrations of 2.96 × 10⁻⁶. -6 2.24×10 -7 6.53×10 -9 8.30×10 - ¹¹、1.33×10 -8 and 1.27×10 -8 M. The vegetative growth medium may further contain one or more of the following micronutrients: H3BO3, ZnSO4. 7H2O, MnSO4 H2O, NaMoO4 2H2O, Ni(NO3)2 6H2O, citric acid monohydrate, CuSO4 5H2O and FeSO4 7H2O, with a final concentration of 2.96×10. -5 1.22×10 -5 1.46×10 -5 3.97×10 -7 2.75×10 -7 1.95×10 -4 3.96×10 -7 and 5.4×10 -6 M. Subsequently, non-chlorophyllary algae cells in the logarithmic growth phase in the nutrient medium were mutagenized using chemical substances or ultraviolet light. Figure 3 Step 1). The exemplary non-green algae cells were then passaged into a lipid-producing medium, where a selection or enrichment strategy was applied to the cells (…). Figure 3 (Step 2). Cells can be cultured using a suitable lipid-producing medium. For non-green algae cells, a suitable medium contains the same concentrations of vitamins and micronutrients as used in the nutrient medium. The macronutrients in the lipid-producing medium can be adjusted relative to the nutrient medium to include 25 mM citric acid monohydrate, 50 g / L glucose, and 1.5 mM (NH4)2SO4. The microalgal cells can then be spread onto a suitable solid nutrient medium containing 0.8% agarose to obtain clonal isolates. Figure 3 Step 3). After obtaining suitable clonal isolates, the isolates were tested in lipid-producing medium in a 96-well plate format. Figure 3 Step 4). Using glucose consumption as a surrogate indicator of lipid yield, high glucose-consuming microalgal cell lines can be verified by culturing them in suitable lipid-producing media in test tubes or shake flasks. Figure 3 Step 5). Successfully validated clonal isolates were then passaged multiple times to stabilize the mutants ( Figure 3 Step 6), and then the clonal isolates are purified ( Figure 3 Step 7). Stable clonal isolates can be repeatedly tested in lipid-producing medium. Figure 3 Step 8). Clones deemed phenotypically stable after the second round of testing (e.g., clones with characteristic profiles, glucose consumption, and lipid titer coefficients of variation %cv < 5%) can be used for fermentation validation. Figure 3 (Step 9), while clones that still exhibit phenotypic variation ( Figure 3 Step 8) requires another generation ( Figure 3 Step 6) to construct a stable clonal line. Unless otherwise stated, microalgae (Non-Green Algae) cells are cultured at approximately 28°C, with shaking at 200 rpm for tube or shake flask culture and 900 rpm for block culture.

[0102] Unless otherwise defined, all technical and scientific terms used herein have the meanings commonly understood by one of ordinary skill in the art to which this disclosure pertains. Although any methods and materials similar to or equivalent to those described herein may be used to implement or verify the invention, several exemplary methods and materials are also described herein.

[0103] Microbial cells and the lipids they produce

[0104] The oils provided herein are derived from non-genetically modified microorganisms (microbes), such as oil-producing microalgae, yeast, or bacteria. In some embodiments, the non-genetically modified microorganisms are microalgal cells. In some embodiments, the microalgal cells are non-genetically modified non-green algae species (…). Prototheca (sp.) strains. The non-genetically modified, non-chlorophyll species strains can be prepared using one or more classical strain improvement strategies described herein.

[0105] In some embodiments, the cells provided herein do not contain exogenous genes or exogenous nucleotides encoding exogenous proteins or genes. For example, the cells provided herein do not contain exogenous genes in the lipid biosynthesis pathway. In some embodiments, the cells provided herein do not contain gene disruption of one or more alleles of endogenous genes in the lipid biosynthesis pathway. In some embodiments, the cells provided herein do not contain heterologous insertions in genomic regions encoding endogenous genes in the lipid biosynthesis pathway. Non-limiting examples of genes involved in lipid biosynthesis include: acyl-ACP thioesterase (FAT), Δ-12 fatty acid desaturase (FAD), ketoacyl-ACP synthase (KAS), stearoyl-ACP desaturase (SAD), lysophosphatidyl acyltransferase (LPAAT), ketoacyl-CoA reductase (KCR), hydroxyacyl-CoA dehydratase (HACD), and enoyl-CoA reductase (ECR).

[0106] In some embodiments, the cells provided herein do not contain the exogenous acyl-ACP thioesterase gene. In some embodiments, the cells provided herein do not contain gene disruption of one or more alleles of the endogenous acyl-ACP thioesterase gene. In some embodiments, the cells provided herein do not contain heterologous insertions within the genomic region encoding the endogenous acyl-ACP thioesterase gene. In some embodiments, the endogenous acyl-ACP thioesterase gene is FATA (acyl-ACP A).

[0107] In some embodiments, the cells provided herein do not contain exogenous fatty acid desaturase genes. In some embodiments, the cells provided herein do not contain gene disruption of one or more alleles of an endogenous fatty acid desaturase gene. In some embodiments, the cells provided herein do not contain heterologous insertions within the genomic region encoding an endogenous fatty acid desaturase gene. In some embodiments, the endogenous fatty acid desaturase gene is Δ-12 fatty acid desaturase. In some embodiments, the endogenous fatty acid desaturase gene is FAD2.

[0108] In some embodiments, the cells provided herein do not contain an exogenous ketoacyl-ACP synthase gene. In some embodiments, the cells provided herein do not contain gene disruption of one or more alleles of an endogenous ketoacyl-ACP synthase gene. In some embodiments, the cells provided herein do not contain heterologous insertions within the genomic region encoding an endogenous ketoacyl-ACP synthase gene. In some embodiments, the endogenous ketoacyl-ACP synthase gene is KASI, KASII, or KASIII.

[0109] In some embodiments, the cells provided herein do not contain an exogenous stearoyl-ACP desaturase gene. In some embodiments, the cells provided herein do not contain gene disruption of one or more alleles of an endogenous stearoyl-ACP desaturase gene. In some embodiments, the cells provided herein do not contain heterologous insertions within the genomic region encoding an endogenous stearoyl-ACP desaturase gene. In some embodiments, the endogenous stearoyl-ACP desaturase gene is SAD2.

[0110] In some embodiments, the cells provided herein do not contain the exogenous lysophosphatidylacyltransferase gene. In some embodiments, the cells provided herein do not contain gene disruption of one or more alleles of the endogenous lysophosphatidylacyltransferase gene. In some embodiments, the cells provided herein do not contain heterologous insertions within the genomic region encoding the endogenous lysophosphatidylacyltransferase gene.

[0111] In some embodiments, the cells provided herein do not contain gene disruption of the endogenous proton ATPase catalytic subunit A isoform 1 gene or one or more alleles within a 1.5 kb range of the 6S genomic region. In some embodiments, the cells provided herein do not contain heterologous insertions of the endogenous proton ATPase catalytic subunit A isoform 1 gene or within a 1.5 kb range of the 6S genomic region.

[0112] In some embodiments, the cells provided herein do not contain gene disruption of one or more alleles within a 1.5 kb range of the endogenous DAO1B gene. In some embodiments, the cells provided herein do not contain heterologous insertions within a 1.5 kb range of the endogenous DAO1B gene.

[0113] In some embodiments, the cells provided herein do not contain gene disruption of one or more alleles within a 1.5 kb range of the endogenous Thi4 gene. In some embodiments, the cells provided herein do not contain heterologous insertions within a 1.5 kb range of the endogenous Thi4 gene.

[0114] Therefore, the uninterrupted sequences of cells containing endogenous genes or genomic regions provided in this article include FAD2, FATA1, KASII, SAD2, type V proton ATPase catalytic subunit A isoform 1 (6S), DAO1B, and Thi4 as described herein.

[0115] In some embodiments, the cells provided herein contain at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity with any one of SEQ ID NO:1-26 (see Table 11 of this disclosure). In some embodiments, the cells provided herein contain any one of SEQ ID NO:1-26 (genomic regions of CHK22 and CHK100). In some embodiments, the cells provided herein contain SEQ ID NO:1-26 (genomic regions of CHK22 and CHK100).

[0116] In some embodiments, the cells provided herein contain at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity with any one of SEQ ID NO: 1, 3, 5, 7, 9, 11, 13, 15, 18, 19, 21, 23, and 25 (genomic regions of CHK22 and CHK100). In some embodiments, the cells provided herein contain SEQ ID NO: 1, 3, 5, 7, 9, 11, 13, 15, 18, 19, 21, 23, and 25 (genomic regions of CHK22 and CHK100).

[0117] In some embodiments, the lipids provided herein are produced by microalgae. In some embodiments, the microalgae are species selected from a genus of the group consisting of: species of the genus Chlorella ( Chlorella sp. ), species of the genus *Pseudococcus* ( Pseudochlorella sp.), species of the genus *Heterococcus* ( Heterochlorella sp. ), no green algae species ( Prototheca sp. ), species of the genus Arthrospira ( Arthrospira sp. Euglena species ( Euglena sp. ), species of the genus Micrococcus ( Nannochloropsis sp. ), species of the genus *Phaeodactylum* ( Phaeodactylum sp. ), species of the genus Chlamydomonas ( Chlamydomonas sp. ), species of the genus Scenedesmus ( Scenedesmus sp. ), Ostreococcus Species, species of the genus *Gyrophyta* ( Selenastrum sp. ), species of the genus *Rhodophyta* ( Haematococcus sp. ), Rhomboidella ( Nitzschia ), Dunaliella genus ( Dunaliella ), species of the genus *Nyctaginea* ( Navicula sp. ), species of the genus *Cyclophora* ( Trebouxia sp. ), species of the genus *Pseudococcus* ( Pseudotrebouxia sp. ), Vavicula Species, species of the genus *Bractocybe* ( Bracteococcus sp. ), species of the genus Heterophyta ( Gomophonema sp. ), species of the genus Watanabe ( Watanabea sp. ), species of the genus *Botrytis* ( Botryococcus sp. ), species of the genus Tetrapanax ( Tetraselmis sp. ) and species of the genus *Isorrhiza* ( Isochyris sp. In some embodiments, the microalgae are species of the genus *Non-green algae* (…). Prototheca sp. In some embodiments, the microalgae is a mulberry-shaped non-green algae (…). P. moriformis ) strain. In some embodiments, the microalgae is Wickham's greenless algae ( P. wickerhamii ) strain.

[0118] In some embodiments, the microalgae cells described herein for producing microbial lipids are derived from the UTEX 1435 basal strain. In some embodiments, the cells provided herein may be derived from the UTEX 1533 basal strain. In some embodiments, the cells provided herein are derived from a basal strain having a 23S ribosomal DNA sequence having at least 80%, at least 85%, at least 90%, at least 95%, or 100% identity with SEQ ID NO:30 or SEQ ID NO:31. In some embodiments, the cells provided herein have a 23S ribosomal DNA sequence having at least 80%, at least 85%, at least 90%, at least 95%, or 100% identity with SEQ ID NO:30 or SEQ ID NO:31.

[0119] In some embodiments, the oils provided herein may be produced by an oil-producing yeast. In some embodiments, the oil-producing yeast is a species selected from a genus of the group consisting of: Candida species (… Candida sp. Cryptococcus species ( Cryptococcus sp. ), species of the genus Debali ( Debaromyces sp. ), species of the genus Nematophora ( Endomycopsis sp. ), species of the genus *Geotrichum* ( Geotrichum sp. ), species of the genus Pichia pastoris ( Hyphopichia sp. ), species of the genus *Olecosomyces* ( Lipomyces sp. Pichia pastoris species ( Pichia sp. ), Rodotorula Species, species of the genus *Rhodotorula* ( Rhodotorula sp. ), species of the genus *Pterospora* ( Sporobolomyces sp. ), species of the genus *Stameria* ( Starmerella sp. ), species of the genus *Cytomyces* ( Torulaspora sp. ), species of the genus Trichosporium ( Trichosporon sp. ), species of the genus *Wickhamia* ( Wickerhamomyces sp. ), species of the genus Yersinia ( Yarrowia sp. ) and species of the genus Zygomycetes ( Zygoascus sp. ).

[0120] In some embodiments, the oils provided herein are obtained from or produced by oil-producing bacteria. In some embodiments, the oil-producing bacteria are species selected from a genus of the group consisting of Xanthomonas oryzae (…). Flavimonas oryzihabitans ), Pseudomonas aeruginosa ( Pseudomonas aeruginosa ), species of the genus Moroccoccus ( Morococcus sp. ), Rhodopseudomonas spheroidae ( Rhodobacter sphaeroides ), Rhodococcus turbidus ( Rhodococcus opacus ), Rhodococcus rubrum ( Rhodococcus erythropolis Streptomyces jeddarii ( Streptomyces jeddahensis ), species of the genus *Pseudomonas* ( Ochrobactrum sp. ), species of the genus Arthrobacter ( Arthrobacter sp. Nocardia species ( Nocardia sp. ), species of the genus Mycobacterium ( Mycobacteria sp. ), species of the genus *Gordonella* ( Gordonia sp. ), species of the genus *Ketococcus* ( Catenisphaera sp. ) and species of the genus Dietrich ( Dietzia sp. ).

[0121] This article also provides bioreactors containing non-naturally occurring microorganisms. For example, these bioreactors contain oil-producing non-naturally occurring microorganisms and the oils produced by said microorganisms.

[0122] While in many embodiments the oils provided herein are derived from non-genetically modified microorganisms or classically modified microorganisms, in other embodiments the oils provided herein are derived from genetically modified microorganisms, such as oleogenetic microalgae, yeasts, or bacteria. In some embodiments, the oils provided herein are derived from classically modified microorganisms that are subsequently genetically modified to produce genetically modified microorganisms. In some embodiments, the genetically modified microorganisms are genetically modified non-green algae species (…). Prototheca sp. ) strain.

[0123] Improved classic strains

[0124] This article uses the terms "classical strain improvement," "classical microalgal strain improvement," or "classical microalgal cell improvement" to describe strategies for selecting organisms with a desired phenotype (e.g., high palmitic acid oil production). Classical strain improvement (also known as "mutation breeding") involves exposing organisms to chemicals or radiation to produce mutants with the desired trait. This type of classical strain improvement method introduces random or semi-random mutations, thereby allowing screening for strains that exhibit the desired trait due to random mutagenesis. Multiple rounds of mutagenesis and screening cycles can be performed using one or more mutagens to obtain strains with the desired phenotype. Ultraviolet (UV) light can be used to introduce random mutations into the nuclear genome of microorganisms. Chemical mutagens include compounds that inhibit or disrupt the biosynthetic processes of microorganisms, such as antibiotics, antifungals, or carcinogens. Non-limiting examples of chemical mutagens include ICR-191, ethyl methanesulfonate (EMS), and 4-nitroquinoline-1-oxide (4-NQO). Non-limiting examples of chemical mutagens also include acridine mutagens, amino acid analogs, fatty acid biosynthesis inhibitors, cholesterol biosynthesis inhibitors, mTOR inhibitors, and membrane solubilizers. Combinations of chemical mutagens can also be used simultaneously (or sequentially) for mutagenesis. After mutagenesis, selectors or enrichment agents can be used to select or enrich the target strain. Non-limiting examples of enrichment agents include L-canavanine, cyanobacterium, triparanol, clomiphene, clomiphene citrate, clotrimazole, terfenadine, fluphenazine, AZD8055, BASF 13-338, chlorpyrifos, clomiphene, PF-042110, and phenylethyl alcohol, as well as combinations of enrichment agents.

[0125] The term "isolated cell" as used in this article refers to the microalgae cells or other microorganisms described herein, which have been isolated from their natural environment and cultured and cloned so that all clones are identical.

[0126] The methods provided herein include classic strain improvement methods for enhancing strain productivity, carbon yield, and palmitic acid content. The glucose consumption rate of microbial cells is a highly predictive indicator of lipid titer and is well known in the art. Therefore, the glucose consumption rate can be used as an enrichment tool in mutant screening processes. The methods provided herein may include one or more of the following: determining the total lipid titer of cells, determining the fatty acid profile of lipids, or determining the C16:0 (e.g., palmitic acid) content of lipids. Furthermore, the methods provided herein may include analyzing cell culture media to determine the glucose consumption rate, total lipid titer, fatty acid profile, C16:0 (e.g., palmitic acid) content, and TAG profile.

[0127] The high palmitic acid oil disclosed herein

[0128] The high palmitic acid lipids of the microbial strains (e.g., microalgae strains) described in this article were obtained from isolated clonal cells treated using the classic strain modification strategy described in this article. An exemplary strain is *Amorphophallus* (a type of algae). Prototheca Microalgae strains, such as Wickham Greenless ( P. wickerhamii ) or mulberry-shaped without green algae ( P. moriformis ).

[0129] The complexity and physical properties of oils can be assessed using the fatty acid and TAG spectra of microalgal oil TAG components. The fatty acid spectrum is a measure of fatty acid composition, determined by transesterification of the oil to generate fatty acid methyl esters (FAMEs), followed by quantitative analysis of fatty acid types using gas chromatography / FID equipped with a flame ionization detector. Therefore, fatty acid content can be determined via GC / FID. Since TAGs consist of three fatty acids arranged along the glycerol backbone of the TAG molecule, the possible number of isomers at different positions of the TAG can be limited by the cube of the number of fatty acid types in the oil. The TAG spectrum provides the relative amounts of various TAG types in the oil, which can be obtained by TAG fractionation detection of the oil using liquid chromatography-time-of-flight mass spectrometry (LC / TOF-MS) equipped with an atmospheric pressure chemical ionization (APCI) source.

[0130] In some embodiments, the oils provided herein have a high palmitic acid content. For example, the fatty acid content of the TAG component of the oils provided herein may have a high palmitic acid level, comparable to that in palm oil derived from palm oil.

[0131] In some embodiments, the oils provided herein have a high palmitic acid content. For example, the fatty acid content of the TAG component of the oils provided herein may have a high palmitic acid level, comparable to that in palm oil derived from palm oil.

[0132] In some embodiments, the oils provided herein contain at least 30%, at least 40%, at least 50%, or at least 60% saturated fatty acid content. For example, the oils provided herein have a C16:0 content of at least about 30%, at least about 31%, at least about 32%, at least about 33%, at least about 34%, at least about 35%, at least about 36%, at least about 37%, at least about 38%, at least about 39%, at least about 40%, at least about 41%, at least about 42%, at least about 43%, at least about 44%, at least about 45%, at least about 46%, at least about 47%, at least about 48%, at least about 49%, at least about 50%, at least about 51%, at least about 52%, at least about 53%, at least about 54%, at least about 55%, at least about 56%, at least about 57%, at least about 58%, at least about 59%, at least about 60%, or higher.

[0133] In some embodiments, the oils provided herein have a fatty acid content of at least 30%, at least 40%, at least 50%, or at least 60% or more of C16:0 fatty acids. In some embodiments, the C16:0 fatty acids comprise palmitic acid.

[0134] In some embodiments, the oils provided herein have a fatty acid content comprising at least 40%, at least 45%, or at least 50% or more of a TAG component containing C18:1 fatty acids. In some embodiments, the C18:1 fatty acids comprise oleic acid.

[0135] In some embodiments, the oils provided herein have a fatty acid content comprising less than 8%, less than 7%, less than 6%, less than 5%, or less of a TAG component containing C18:2 fatty acids. In some embodiments, the C18:2 fatty acids comprise linoleic acid.

[0136] In some embodiments, the oils provided herein contain less than 5%, less than 4%, less than 3%, less than 2%, less than 1%, less than 0.5%, less than 0.1%, or less.

[0137] In some embodiments, the oils provided herein contain polyunsaturated fatty acids. In some embodiments, the polyunsaturated fatty acids comprise C18:2. In some embodiments, the oils have a C18:2 content of about 3% to about 9%, about 4% to about 8%, or about 5% to about 8%. In some embodiments, the oils provided herein may have a C18:2 content of less than 8%, less than 7%, less than 6%, or lower.

[0138] In some implementations, the fatty acid content of the TAG component may include about 35% to about 60% C16:0 fatty acids.

[0139] In addition to fatty acid profiling, oils and fats can be further evaluated by sterol profiling or composition. Sterol composition can be determined by mass spectrometry, such as gas chromatography-mass spectrometry (GC-MS), liquid chromatography-mass spectrometry (LC-MS), tandem mass spectrometry (MS / MS), and liquid chromatography coupled with gas chromatography followed by flame ionization detection (LC-GC-FID). The concentration of different sterols present in oils and fats can be expressed as mg sterol / 100 g oil. Non-limiting examples of sterols include ergosterol, ergoster-8(14)-en-3-ol (3β), 5.Xi.-ergoster-7-en-3β-ol, 9,19-cyclolanostane-24-en-3-ol (3β), and 9,19-cyclolanostane-3-ol-24-methylene (3β). In some embodiments, ergosterol may be present in an amount of at least about 30 mg / 100 g oil. In some embodiments, 5.Xi.-ergoster-7-en-3β-ol may be present at least about 25 mg / 100 g of oil. In some embodiments, 9,19-cyclolanostane-24-en-3-ol (3β) may be present at least 15 mg / 100 g of oil. In some embodiments, 19-cyclolanostane-3-ol, 24-methylene (3β) may be present at least about 25 mg / 100 g of oil.

[0140] In some embodiments, the oils provided herein may contain less than 5%, less than 4%, less than 3%, less than 2%, less than 1%, less than 0.5%, less than 0.1%, or less monoacylglycerol (MAG).

[0141] In some embodiments, the oils provided herein may contain less than 5%, less than 4%, less than 3%, less than 2%, less than 1%, less than 0.5%, less than 0.1%, or less diacylglycerol (DAG).

[0142] The microalgae-derived oils of this disclosure can serve as a substitute for palm oil in a variety of applications requiring the utilization of palmitic acid. The microalgae-derived oils of this disclosure can provide palmitic acid, similar to palm sap oil and intermediate palm fractions, which are valuable due to their high levels of structured fatty acid POPs. However, the microalgae-derived oils of this disclosure also have advantages over palm oil and its various fractions due to their reduced C18:2 fatty acid content. Compared to palm oil, the microalgae-derived oils of this disclosure can contain lower levels of C18:2. Since C18:2 fatty acids are easily oxidized, oils containing high levels of C18:2 are more prone to oxidative degradation. Therefore, the oils of this disclosure have advantages in the production of food and nutritional products requiring long shelf lives. The microalgae-derived oils of this disclosure also have advantages over palm oil due to their reduced MAG and DAG levels. MAG and DAG are more sensitive to oxidation than TAG. During the heat treatment process of vegetable oil refining, MAG and DAG can also serve as precursors for the formation of glycidyl esters (harmful processing contaminants).

[0143] For at least the reasons mentioned above, the oils described in this disclosure have advantages in the production of foods and nutritional products with the highest requirements for food safety.

[0144] Food, nutrition, and home and personal care applications

[0145] The oils described herein can be used alone or in combination with one or more excipients for a variety of food applications, including but not limited to food products (such as food-grade oils, cooking oils, frying oils, coating agents, salad dressings, spreads, and frozen desserts), pharmaceuticals, nutritional supplements, nutritional health products, meal replacement foods, infant formula, beverages, flavoring agents, and food additives.

[0146] Furthermore, the oils disclosed herein can be used in the fields of personal care and home care as substitutes for palm oil and palm oil fractions, which are commonly used as raw materials for the preparation of surfactants and their derivatives.

[0147] Example

[0148] Example 1. Construction of a classic modified microalgal strain capable of producing triglyceride oils highly enriched with palmitic acid.

[0149] Strains Acquisition, Isolation and Characterization

[0150] Wickham Algae-Free Prototheca wickerhamii The strain (UTEX 1533) was obtained from the Algal Collection (UTEX) at the University of Texas at Austin. Analysis of the 23S ribosomal DNA (rDNA) sequence (SEQ ID NO:30) of UTEX 1533 showed that UTEX 1533 is related to *Mulberry-shaped* achlorophyll (…). Prototheca moriformis The strain UTEX 1533 is closely related to UTEX 1435 (SEQ ID NO:31). The 23S rDNA sequence of UTEX 1533 shares 100% sequence identity with the published 23S rDNA sequence of UTEX 1435 (Figure 1). The UTEX 1533 strain obtained from UTEX was repeatedly passaged on solid media containing multiple antibiotics and antifungal agents, followed by passage on antibiotic-free solid media, confirming a single cell type and homogeneous morphology, thus verifying its status as a strain. This parental strain was named "Strain 0," and is also referred to as CHK22 in this paper.

[0151] First round of mutation

[0152] The classic strain CHK22 was modified to improve its production capacity, carbon yield, and palmitic acid content. The strain lineage of the mutants constructed in the examples is shown in [link to example]. Figure 2A and 2B An overview of the process flow for mutagenesis, trait screening, and high-throughput automated screening steps in the improvement process can be found in [link to relevant documentation]. Figure 3 .like Figure 2A and 2B As shown, algal cells are cultured in a specified vegetative growth medium composed of the following components: NaH2PO4, K2HPO4, citric acid monohydrate, and MgSO4. 7H2O, CuCl2 The macronutrients, consisting of 2H₂O, glucose, (NH₄)₂SO₄, and Sigma-Aldrich antifoaming agent 204, were final concentrations of 13.6 mM, 11.4 mM, 5 mM, 0.15 mM, 40 g / L, 7.5 mM, and 0.23 g / L, respectively. The vitamins in the vegetative growth medium were: thiamine hydrochloride, D-pantothenic acid, biotin, cyanocobalamin, riboflavin, and pyridoxine hydrochloride, with final concentrations of 2.96 × 10⁻⁶ g / L. -6 2.24×10 -7 6.53×10 -9 8.30×10 - ¹¹、1.33×10 -8 and 1.27×10 -8 M. The micronutrients in the vegetative growth medium used are as follows: H3BO3, ZnSO4 7H2O, MnSO4 H2O, NaMoO4 2H2O, Ni(NO3)2 6H2O, citric acid monohydrate, CuSO4 5H2O and FeSO4 7H2O, with a final concentration of 2.96×10.-5 1.22×10 -5 1.46×10 -5 3.97×10 -7 2.75×10 -7 1.95×10 -4 3.96×10 -7 and 5.4×10 -6 M. Cells in the logarithmic growth phase of the nutrient medium were mutagenized using chemical reagents or ultraviolet light. Figure 3 Step 1). The cells were then passaged into lipid-producing medium, where a selection / enrichment strategy was applied (…). Figure 3 (Step 2).

[0153] The lipid-producing medium contains the same types and concentrations of vitamins and micronutrients as the vegetative growth medium. Compared to the vegetative medium, the macronutrients in the lipid-producing medium are adjusted to include 25 mM citric acid monohydrate, 50 g / L glucose, and 1.5 mM (NH4)2SO4. Microalgal strains are spread onto a solid nutrient medium containing 0.8% agarose to obtain clonal isolates. Figure 3 Step 3), followed by analysis of these isolates in lipid-producing medium using a 96-well plate. Figure 3 Step 4).

[0154] Using glucose consumption as a surrogate indicator of lipid yield, strains with high glucose consumption can be verified in lipid-producing media in test tube or shake flask formats. Figure 3 Step 5). Successfully validated isolates were subjected to multiple generations of subculturing to stabilize the mutation ( Figure 3 Step 6), followed by purification of the clonal isolates ( Figure 3 (Step 7) and then perform a subsequent re-test in the lipid-producing medium ( Figure 3 Step 8). Clones considered phenotypically stable (characteristic profile, glucose consumption, and lipid titer coefficient of variation %cv < 5%) were further validated through fermentation. Figure 3 (Step 9), while ( Figure 3 Clones that still exhibit variability in step 8) need to be passaged again. Figure 3 Step 6) to construct a stable cell line. Unless otherwise specified, cells are cultured at approximately 28°C, with shaking at 200 rpm for tube or shake flask culture and 900 rpm for block culture.

[0155] like Figure 3In detail, CHK22 cells were chemically mutagenized with 44 μM 4-nitroquinoline-1-oxide (4-NQO), or sham-mutated by adding only the mutagen solvent dimethyl sulfoxide (DMSO). Sodium thiosulfate was added to inactivate the mutagen, followed by repeated washing with water to remove the sodium thiosulfate. Cells were then cultured in a glucose-limited growth medium (the same as the nutrient medium, but containing 5 g / L glucose). The mutagenized and sham-mutated populations were subsequently cultured for five days in a lipid-producing medium at 38°C. The optimal lipid-producing temperature for CHK22 is typically 28-32°C; therefore, a temperature higher than optimal was used as a stress factor to give an advantage to mutants that tend to exhibit higher palmitate levels. Similar phenomena have been observed in fungal model systems and some commercially viable oil-producing higher plants when they are exposed to high temperatures for extended periods during growth or culture. At the end of a 5-day lipid production culture at 38°C, cells were collected and then treated at 65°C for 4 minutes. Based on the results of a range-exploration experiment conducted in the same manner, >99% of the cell population was typically killed at this temperature range and treatment duration. After heat treatment, the cells were recultured in a glucose-limited growth medium for three days, then diluted and plated. Mutant clones were then picked, and their glucose consumption rate and fatty acid profile were evaluated using a 72-hour lipid production assay based on 96-well plates. Figure 2A The first three rows of Table 1 show the glucose consumption rate and fatty acid profile values ​​(three replicate tests) of the CHK22 parent strain. The last three columns of Table 1 show the CHK22 mutants. As shown in Table 1, the palmitic acid content of CHK22 mutant 1 is nearly 8% higher than that of the CHK22 parent strain, although its glucose consumption rate is significantly lower, which is a sign of lower lipid titer.

[0156] Table 1: Fatty acid profiles of selected CHK22 mutant strains that exhibited high glucose consumption and elevated palmitate levels in a 96-well plate lipid production assay.

[0157] like Figure 2A As shown, after the mutant strain was cultured in lipid-producing medium (0.5 mL) at 28°C and 900 rpm for 72 hours, its glucose consumption was measured. The fatty acid composition of isolates with high glucose consumption levels was further analyzed, and the lead strains are shown in Table 1.

[0158] To further adapt CHK22 mutant 1 to its altered fatty acid composition and enhance its lipid production capacity, CHK22 mutant 1 was continuously passaged without any selection pressure and then plated on solid medium to obtain single colonies. The subclones were screened in lipid production assays to assess the phenotypic stability of the lineage in terms of glucose consumption rate and fatty acid profile (e.g., %cv < 5%). After one round of continuous passages, the mutant's phenotype remained unstable. Several subclones retaining a higher palmitic acid level phenotype and an increased glucose consumption rate were selected for several additional rounds of continuous passages and stability assessments. After a total of five rounds of continuous passages and stability assessments, a stable strain was identified and named CHK100. CHK100 had approximately 5% higher palmitic acid content than the parental CHK22 strain, and its lipid content, cell dry weight, and lipid titer were all higher than those of the parental CHK22 strain. Figure 2A ).

[0159] Table 2: Test tube-based experiments on strain CHK100 (a classic modified derivative of strain CHK22) showed that the C16:0 content was increased and the lipid potency was improved.

[0160]

[0161] like Figure 2A As shown, all strains were tested under standard lipid-producing conditions: the strains were cultured in double replicates in 10 mL of lipid-producing medium, and the cultures were grown with shaking at 28 °C and 200 rpm for 121 hours; then 1 mL of biomass was taken and applied to a polycarbonate filter membrane, washed with an equal volume of Milli Q water, and placed in a pre-weighed glass vial, which was then placed at -80 °C for 30 minutes. The vial containing the filter membrane and frozen biomass was freeze-dried overnight, the weight was recorded, and the filter membrane with the dried biomass was subjected to direct transesterification reaction, followed by quantitative detection of FAME by GC / FID.

[0162] mutagenesis of CHK100

[0163] CHK100 cells were recovered from 24-hour autogenous lipid-producing cultures and chemically mutagenized for 30 minutes at 32°C using 22 μM 4-nitroquinoline-1-oxide (4-NQO); or sham mutagenesis was performed using only the mutagen solvent dimethyl sulfoxide (DMSO). Sodium thiosulfate was added to inactivate the mutagen, followed by repeated washing with water to remove the sodium thiosulfate. Cells were then recultured in a glucose-limited growth medium. The mutagenized and sham-mutated populations were then cultured independently: first in seed medium at 38°C for 24 hours, then in lipid-producing medium at 38°C for three days. At the end of the three-day lipid-producing culture at 38°C, cells were collected and subsequently exposed to 65°C for 1, 2, 3, or 4 minutes, respectively. After heat treatment, surviving cells were recultured in glucose-limited growth medium for three days, then diluted and plated. Surviving cells were only recovered after a 1-minute treatment at 65°C. Mutant clones were then selected, and a 72-hour lipid production assay based on 96-well plates was used to evaluate their glucose consumption rate and fatty acid profile. Figure 2A and 2B Two of the identified mutants (Table 3; marked in bold and underline) had palmitic acid content 4-4.5% higher than the CHK100 parent strain, while maintaining a reasonable glucose consumption rate, which is usually a marker of strains with the desired lipid titer.

[0164] Table 3: Fatty acid profiles of selected mutant strains that exhibited higher glucose consumption rates (g / L·d, i.e., grams cultured per liter of medium per day) and elevated palmitic acid levels in 96-well plate lipid assays.

[0165] The CHK100 mutant strain was cultured in the above-mentioned lipid-producing medium (0.5 mL) with shaking (900 rpm) for 72 hours, and then the glucose consumption was measured. The fatty acid composition of the isolates with high glucose consumption was further analyzed. Table 3 lists the summary data comparison between the lead strain and the CHK100 parental control group.

[0166] The mutants were rescreened in a 5-day lipid production study using bioreactor tubes to quantitatively assess their fatty acid profiles, lipid productivity, and triglyceride (TAG) distribution, with particular attention to the levels of valuable palmitic acid-oleic acid-palmitic acid (POP)-containing TAGs. POP has high application value as a substitute for traditional POP derived from palm oil; traditional POP requires extensive industrial processing and faces supply issues due to climate change.

[0167] As shown in Table 4, the palmitic acid content of one of the mutants, “…Blk07;F02” or “CHK100 mutant isolate 2”, was consistently about 4.5% higher than that of the CHK100 parent strain. In addition, its lipid potency and oil content were also moderately increased compared with the parent strain. Figure 2A The phylogenetic evolution of the high palmitic acid strains obtained by modifying the classical strains described above is shown, and the oleic acid (C18:1) and palmitic acid (C16:0) levels of each strain in the phylogenetic lineage are listed. The mutagenesis method used in each step is indicated above each arrow, and the enrichment strategy used in conjunction with each mutagenesis strategy is indicated below the arrow. "...Blk07;F02" is also referred to in this disclosure as "CHK mutant isolate 2".

[0168] Table 4: Tube-based experiments on the CHK100 mutant showed increased C16:0 levels and improved lipid titer. The method for determining “dry cell weight” (“DCW”) was as follows: 1 mL of culture medium was placed on a pre-weighed glass filter membrane atop a sintered glass funnel, vacuum filtered, and washed with 5 mL of water. The filter membrane was then freeze-dried to constant weight and reweighed to determine the DCW for each sample. “Non-lipid biomass” (“NLB”) was determined by subtracting lipids (g / L) from DCW. “Per-cell yield” (“PCP”) was determined by dividing NLB by lipid titer.

[0169]

[0170] All strains included in Table 4 were tested under standard lipid production conditions: the strains were cultured in double replicates in 10 mL of lipid production medium, and the cultures were grown with shaking at 28°C and 200 rpm for 121 hours; then 1 mL of biomass was taken and applied to a polycarbonate filter membrane, washed with an equal volume of Milli Q water, and transferred to a pre-weighed glass vial, which was placed at -80°C for 30 minutes. The vial containing the filter membrane and frozen biomass (cells) was freeze-dried overnight, the weight was recorded, and the filter membrane with the dried biomass was subjected to direct transesterification reaction, followed by quantitative detection of FAME by GC / FID. The abbreviations included in Table 4 are: DCW (dry weight of cells), NLB (non-lipid biomass), and PCP (yield per cell, defined as [lipid potency (g / L)] / NLB).

[0171] Figure 2BThe subsequent progression of the mutant isolate “...Blk07;F02” (also referred to in this paper as strain “CHK mutant isolate 2”) is shown. This isolate was continuously passaged and screened in lipid assays (using the same method as above) to obtain the stable strain CHK224. FAME analysis showed that the palmitic acid content in its crude oil was 37%. Another stability screening based on SSID 1447 yielded a subclone “C06” (Figure 2B) and an intermediate strain CHK243u. This intermediate strain underwent further continuous passages, and after lipid production assays, the subclone “A10” was obtained. Subclone A10 is characterized by a 39% palmitic acid level in the isolated oil. After another round of passages and lipid production assays (SSID 1515), subclone A10 branched its lineage. One branch of this lineage produced clone “E04”, which, after further subculturing and stability testing in lipid-producing medium, yielded stable strain CHK263, characterized by 40% palmitic acid in the isolated crude oil.

[0172] like Figure 2B As shown, the second branch point from clone 1515 produced an unstable strain, "subclone E07," which was later named CHK256u. Subsequently, the lipid-producing phase culture of CHK256u was taken and exposed to 2.8... M 4-NQ cells were treated at 30°C for 30 minutes and then recovered in fresh nutrient medium at 30°C for 24 hours. The mutant population of exposed CHK256u cells was then cultured in lipid-producing medium, exposed to 100 μM chlorpyrifos (a herbicide) during culture, and treated at 35°C for 72 hours. Surviving cells were recovered and screened. The first clone obtained from SSID1642 screening was the mutant “clone F07,” which produced crude oil with a palmitic acid content of 42%; this clone was named CHK 268u. CHK268u was subsequently passaged continuously, and further tested using an lipid-producing assay (SSID 1710). After screening SSID 1710 cells, “Blk08,F04” was cloned from it. This strain, when cultured in lipid-producing medium at 32°C, produced microalgal oil with 49.9% palmitic acid content.

[0173] Liquid Chromatography-Mass Spectrometry (LCMS) Analysis Method

[0174] Triacylglycerol (TAG) spectra of CHK100 and its mutant strains were analyzed using liquid chromatography-mass spectrometry (LC-MS). TAG was extracted from dried biomass of *P. moriformis* using mechanical crushing with ceramic beads and vigorous stirring, and then added to a 3:1 (v / v) toluene / 2-propanol solution. The filtered extract was then injected into an Agilent 1290 Infinity II ultra-high performance liquid chromatography system coupled with a 6470B triple quadrupole mass spectrometer and an APCI ion source, following the methods described in Co, ED et al. (Co, ED, Koutchekinia, M., Carney, JR et al., “Matching the Functionality of Single-Cell Algal Oils with Different Molecular Compositions”). J.Am.Oil Chem.Soc. The parameters described in (91:533-48, 2014) were analyzed, and the total ion current chromatogram (TIC) is shown below. Figure 4 . Figure 4 The LCMS data shown demonstrates that the naming of the tags in this paper is not location-specific.

[0175] LCMS determination of positional isomers

[0176] The LCMS method described in this article cannot achieve chromatographic separation of positional isomers, but it can qualitatively assess the position specificity of the major isomer based on the abundance of diacylglycerol (DAG) ions generated from TAG fragmentation. In the LC-APCI-MS analysis of TAG, sn-1 and sn-3 The loss of fatty acids is more energy-efficient than sn-2 The loss of fatty acids at the 1, 2-position is more favorable, resulting in a higher abundance of diacylglycerol ions formed from the former fragments. For example, for 1,2-dispalmitoyl-3-oleoylglycerol (PPO), [OP] can be observed. + DAG ions (m / z 577) and [PP] + The ratio of DAG ions (m / z 551) is close to 1:1; this is because the contribution of 1-palmitoyl-3-oleoyl DAG species is relatively rare ([OP]). + The same applies to the types of DAG ions (m / z 577). For 1,3-dipalmitoyl-2-oleoylglycerol (POP), a higher abundance of [OP]+ DAG ions (m / z 577) can be observed because... sn-1 or sn-3Removal of the palmitoyl group at the OP position generates a [OP]+ DAG ion (m / z 577), while the corresponding [PP]+ DAG ion (m / z 551) can only be generated through... sn-2 The removal of the oleyl group produces the product, a rare pathway. For AAB and ABA triacylglycerols, linear calibration curves can be constructed between the [AA]+ / [AB]+ ratio and a mixture of pure positional isomers of AAB and ABA with known compositions. The methods used are described, for example, in Byrdwell's literature (Byrdwell WC., “The updated bottom-up solution applied to mass spectrometry of soybean oil in a dietary supplement gelcap,”). Anal. Bioanal Chem. (407(17): 5143-60, 2015). Using this method, the precise composition of each positional isomer can be calculated based on the above linear relationship, and it can also be simplified by using only a two-point calibration curve at the endpoints of the calibration curve. This can be expressed by the following equation:

[0177] according to Figure 3 The microalgal strains with high palmitic acid production obtained by the process shown, the CHK100 control, and the mass spectra and DAG ion ratios of palm oil are shown in the figure. Figure 5-8 . Figure 9-12 Mass spectra and DAG ion ratios of natural palm oil and 1,3-dicalpalmitoyl-2-oleoylglycerol and 1,2-dicalpalmitoyl-3-oleoylglycerol purchased from Larodan Research Chemicals are shown. Table 5 lists the abundance of [OP]+ and [PP]+ DAG ions for each sample, as well as the calculated %POP in the unpurified oil TAG fraction (including biological replicates, named replicate A and replicate B; instrumented replicates, named r001 and r002). Figure 9 The red palm oil analyzed was Nutiva® Nurture Vitality, a product purchased from Berkeley Bowl, Berkeley, California. Figure 10 and 11 The analytical standards for 1,3-dipalmitoyl-2-oleoylglycerol and 1,2-dipalmitoyl-3-oleoylglycerol were purchased from Larodan Research Chemicals.

[0178] Table 5: Calculated [OP] + / [PP] +DAG ion abundance and %POP calculated based on its ratio to pure POP and PPO regiomeric standards derived from palm oil, compared with the use of Figure 2A and 2B The screening methods shown are derived from a variety of classic improved methods. P. moriformis The triglycerides extracted from the isolates were compared.

[0179]

[0180] Table 6 shows the complete triglyceride profiles (area %) of the various classic modified derivatives of CHK100, the parental CHK100 control, and red palm oil. Furthermore, as shown in Table 6, sample CHK100 mutant isolate 2 (repeat A) had a higher POP content and a lower PPO content compared to red palm oil. Red palm oil also had higher levels of trimalmitoylglycerols. All other triglyceride names are non-position-specific. Abbreviations used in Table 6 and elsewhere are as follows: LLL: Linoleic acid-linoleic acid-linolenic acid glyceride LLP: Linoleic acid-linoleic acid-palmitoyl glyceride LOL: Linoleic acid-oleic acid-linoleic acid glyceride MLP: Myristic acid-linoleic acid-palmitoyl glyceride MOL: Myristic acid-oleic acid-linoleic acid glyceride MOP: Myristic acid-oleic acid-palmitoyl glyceride OOA: Oleic acid-oleic acid-arachidic acid glyceride OOB: Oleic acid-oleic acid-behenate glyceryl ester OOL: Oleic acid-oleic acid-linoleic acid glyceride OOLn: Oleic acid-oleic acid-linolenic acid glyceride OOM: Oleic acid-oleic acid-myristate glyceride OOO: Oleic acid-oleic acid-glyceryl ester OOP: Oleic acid-oleic acid-palmitoyl glyceride OOS: Oleic acid-oleic acid-glyceryl stearate PCP: Glyceryl palmitate-decanoate-palmitoyl palmitate PLP: Palmitic acid-linoleic acid-glyceryl palmitate PLS: Palmitic acid-linoleic acid-glyceryl stearate PMP: Palmitic acid-myristic acid-glyceryl palmitate POA: Palmitic acid-oleic acid-arachidic acid glyceride POB: Palmitic acid-oleic acid-behenic acid glyceride POL: Palmitic acid-oleic acid-linoleic acid glyceride POP: Palmitic acid-oleic acid-palmitoyl glyceride POLn: Palmitic acid-oleic acid-linolenic acid glyceride POS: Glyceryl palmitate-oleic acid-stearate PPA: Palmitic acid-palmitic acid-arachidic acid glyceride PPO: Palmitic acid-palmitic acid-oleic glyceride PPP: Palmitic acid-palmitic acid-glyceryl palmitate PPS: Palmitic acid-palmitic acid-glyceryl stearate PSS: Palmitic acid-stearic acid-glyceryl stearate SOL: Palmitic acid-oleic acid-linoleic acid glyceride SOS: Stearic acid-oleic acid-glyceryl stearate SSG: Stearic-stearic-gondolic (C18:1n-11) SSID: Strain / Sample Identifier TAG: Unless otherwise stated, triglycerides or triglycerides are not position-specific.

[0181] Table 6: High palmitic acid strains and Nutiva ® Comparison of triglyceride profiles of Nurture Vitality red palm oil

[0182] Unless otherwise specified (such as in the case of POP and PPO), TAG naming is non-position-specific. Figure 12 and 13 This is a graphical representation of the same data shown in Table 6. In Table 6, "ECN" indicates the equivalent carbon number. Specifically, isolate 2 replicate A of the CHK100 mutant showed a higher POP content compared to palm oil. Figure 12 and 13 The red palm oil used as the analytical standard was Nutiva® Nurture Vitality red palm oil. Compared with the CHK100 control and the CHK100 mutant isolate, the palm oil had a higher PPO content and a higher tripalmitate content.

[0183] In addition, FAME analysis was performed on sample CHK100 mutant isolate 2 replicate A (see Table 4) and analytical standard Nutiva® Nurture Vitality Red Palm Oil, and the results showed the palmitate levels of the oil derived from CHK100 mutant isolate 2 of this disclosure.

[0184] Table 7: FAME analysis of red palm oil

[0185] Example 2 Fatty acid profile

[0186] like Figure 14 As shown, the fatty acid profile of CHK100 mutant isolate 2 (a high palmitic acid strain optimized from the classic CHK100 strain using the method described herein) was analyzed using GC-FID (gas chromatography-flame ionization detection). The results revealed the levels of palmitic acid and unsaturated fatty acids, the latter being categorized by the levels of oleic acid and linoleic acid found in the sample. Figure 14 The concentrations (abbreviated as 18:1 and 18:2 respectively) were added together for calculation. The study found that the levels of palmitic acid and unsaturated fatty acids in the microalgal oil described in this paper are comparable to those reported in the literature for palm oil (Sampaio et al., (2011) Steamdeacidification of palm oil). Food and Bioproducts Processing . 89, 383-90).

[0187] Example 3 Triacylglycerol spectrum

[0188] Figure 15 The triglyceride (TAG) profile of an exemplary high palmitic acid strain of this disclosure is shown. This strain was optimized from the classic CHK100 strain and analyzed using LC-MS (liquid chromatography-mass spectrometry). Figure 18 Comparison Figure 2A and 2B The levels of PPP, PPO, and POP positional isomers for each strain are shown, and among them, Figure 15 The strain shown provides results for a different strain.

[0189] Figure 15 The results showed that the level of 1,3-dipalmitoyl-2-oleoylglycerol (POP) in isolate 2 of the classically modified algal strain CHK100 was comparable to the POP level reported in palm oil (Sampaio et al., 2011). The analysis also indicated that this algal strain contained less than 1% tripalmitoylglycerol (TPS). Figure 15 (referred to as PPP in Chinese).

[0190] Example 4. Diacylglycerol and monoacylglycerol spectra

[0191] Both palm oil and palm fractions contain significant levels of incomplete glycerides (Sampaio et al., 2011 & Sasue et al., (2015) "Synthesis of palm oil high in diacylglycerol through direct esterification"). The Malaysian J. of Analytical Sciences . 19(1): 222-29), especially diacylglycerols (DAG) and monoacylglycerols (MAG). According to the literature, palm oil and its fractions typically contain about 2-6% diacylglycerols and 2-5% monoacylglycerols (Sasue et al., 2015). The algal oil described in this paper has a fatty acid and triacylglycerol (TAG) profile similar to that of palm oil, but contains only trace amounts (e.g., <2%) of the total MAG and DAG.

[0192] Existing literature has confirmed that the presence of incomplete glycerides (such as DAG and MAG) can adversely affect the shelf-life stability of products, given their greater susceptibility to oxidative degradation compared to triglycerides (TAG). Similarly, high palmitic acid oils optimized using the classic CHK100 strain also contain less than 6% linoleic acid (expressed as a percentage of total TAG); while palm oil and palm sap oil typically contain 9-12% linoleic acid, making them more susceptible to oxidative degradation.

[0193] Furthermore, the presence of DAG in oils has been identified as a precursor to the formation of processing contaminants, including glycidyl esters, which are generated during the deodorization process of microalgal oils (Destaillats et al. (2012) Glycidyl esters in refined palm (Elaeis guineensis) oil and related fractions. Part I: Formation mechanism). Food Chemistry , 131: 1391-98).

[0194] Therefore, due to the reduced MAG and DAG levels, the high palmitic acid oil obtained by the classic CHK100 strain has improved oxidative stability and is believed to reduce glycidyl ester residues, making the crude oil obtained from this strain significantly more valuable than that obtained by existing strains. Oils with higher oxidative stability increase their application in foods intended for human and animal health and nutrition.

[0195] Example 5 Characterization of high palmitate triglyceride oil produced by classic modified microalgae strains

[0196] The sterol composition of the high palmitic acid refined, decolorized, and deodorized (RBD) triglyceride fats disclosed in this paper was determined by gas chromatography-mass spectrometry and flame ionization. Samples were prepared according to the German standard method F-III for sterols in fats and oils described in the literature by Aitzetmüller et al. (1998) (“Analysis of sterol content and composition in fats and oils by capillary-gas liquid chromatography using an internal standard. Comments on the German sterol method,”). Fett / Lipid (100:429-435), the full text of which is incorporated herein by reference. After adding the internal standard, the oil was saponified. The unsaponifiable fraction was separated using solid-phase extraction. The trimethylsilyl (TMS) derivative of the unsaponifiable fraction was loaded onto an Agilent 8890 gas chromatograph equipped with a 5977B single quadrupole EI-MS and a FID (flame ionization detection) detector. After separation on a DB-5MS UltraInert column (60 m long × 0.25 mm inner diameter × 0.25 μm film thickness), the sample was split between the MS and FID detectors using a capillary split technique (CFT). Mass spectrometry data, combined with retention time comparisons with analytical standards (if available), were used to identify each sterol species. Quantification was performed based on the comparison between the response values ​​of sterol TMS ethers detected by GC-FID and the response values ​​of the internal standard.

[0197] The obtained sterol spectra are shown in Table 8. Contents are expressed as mg / 100 g oil and as an approximate percentage of the total sterols detected. Trace unidentified peaks are not included. Not all sterols were identifiable; those not identified are listed as unknown. Ergosterol was the predominant sterol present in both oils. Several other sterols present in high amounts in RBD oils also include 5.xi.-ergoster-7-en-3(3-ol, (3β)) and 9,19-cyclolanostane-3-ol, 24-methylene (3β), -O-TMS.

[0198] Table 8: Sterol profiles of RBD lipids from strains CHK22 and CHK100

[0199] Example 6: Fatty acid and TAG profiles of clone “Blk08,F04”

[0200] like Figure 16 As shown in Table 9, the classic strain CHK 268Ude was optimized ( Figure 2BThe high palmitic acid strain "Blk08,F04" produced nearly 50% palmitic acid ester when cultured at 32℃, and 47% palmitic acid ester when cultured at 28℃ for the same duration.

[0201] Table 9 shows the results of two biological replicates of clone “Blk08,F04” in vitro at 32°C or 28°C for 5 days. It can be seen that the lipid titer, DCW, and palmitate levels in the resulting oil were higher when cultured at 32°C, but the lipid percentage and yield per cell (PCP; [lipid g / L] / [DCW - lipid g / L]) were lower.

[0202] Figure 17 The TAG profiles of lipids isolated from the same sample cultured at 32°C or 28°C by clone “BLK08,F04” are shown. The isolate produced 45% or 40% POP under the two conditions, respectively.

[0203] Table 9: Experimental results of cloning "Blk08,F04" at 32℃ or 28℃

[0204] Table 10 and Figure 18 The levels of POP and PPO positional isomers and PPP in classic improved strains (i.e., the subject of this disclosure, as shown in Figure 2) and commercially available oils (including palm intermediate fraction (PMF) and red palm oil) are illustrated. PMF is valuable due to its high POP content and is a key component of the structural fats produced through multi-stage fractionation of palm oil fractions. POP, stearic acid-oleic acid-stearic acid (SOS), and palmitic acid-oleic acid-stearic acid (POS) are the major structural fats in cocoa butter. The PMF and algae oils described herein can be used as blend stock with cocoa butter from different origins (whose contents of the three major structural fats may vary) or with other cocoa butter extenders or similar agents that affect the physical properties of these important structural fats. It can be seen that the POP level of clone “BLK08;F04” is significantly higher than that of commercially available palm oil, approximately 70% of that seen in commercially available palm intermediate fraction (PMF). Importantly, in the microalgae-derived oils described in this article, the levels of PPO and PPP, which may adversely affect the melting properties and mouthfeel of candies, were significantly reduced.

[0205] Careful analysis of Table 10 and Figure 18The results demonstrate that Prototheca microalgae cells, lacking the green algae genera, offer superior fat composition and practicality compared to traditional oils such as red palm oil. It should be noted that the two TAGs, PPP and PPO, can disrupt and interfere with the melting properties and mouthfeel of important structural fats (such as cocoa butter). Compared to the crude microalgae oil from the enhanced strains described in this paper, they exhibit superior performance in palm oil and palm oil intermediate fraction (PMF). Figure 18 The levels are elevated in the PPO and PPP (as marked "AAK PMF" in Table 10 below). Note the inherently elevated levels of PPO and PPP in red palm oil, especially PPO in PMF.

[0206] All microalgal oils disclosed herein exhibit PPP and PPO levels significantly lower than those of palm oil (e.g., clone BLK08;F04 shows PPP content of only 65% ​​and PPO level of only 16% of that seen in red palm oil, while POP level is more than 1.9 times that of red palm oil), and its PPO level is 4.7-12.3 times lower than that seen in AAK PMF.

[0207] Table 10: Positional isomers of POP and PPO and PPP levels in classic improved strains and commercially available oils, which are the subject of this disclosure. (Results are also shown in...) Figure 18 .

[0208]

[0209] The sequences in Table 11 represent exemplary insertion sites in greenless algae and can be used to assess the absence of heterologous genes introduced through recombinant engineering in the parental strain. Given certain government regulations on the use and labeling of products produced by or derived from genetically modified organisms (GMOs), the greenless algae strain developed in this application can utilize the aforementioned exemplary sites to demonstrate that the strain has not been engineered. However, the strain may also be recombinantly engineered if necessary.

[0210] Table 11: SEQ ID NOs: 1-26, 30-31 cited in this article

[0211] This disclosure describes and illustrates various embodiments in conjunction with specific examples. However, it should be understood that modifications, alterations, adjustments, or substitutions can be made to the features of the described embodiments without significantly departing from the spirit of the invention. Those skilled in the art will recognize that various changes and modifications can be made to the above embodiments without departing from the scope of this disclosure.

[0212] Implementation Plan

[0213] The following provides several embodiments to illustrate the compositions, preparation methods, and uses of the methods and compositions described herein: Implementation Scheme [1]. An oil derived from microalgae cells comprising a triacylglycerol (TAG) component, wherein the TAG component has a fatty acid content of at least 30% C16:0 fatty acids and at least 40% C18:1 fatty acids, and wherein the oil is produced by modification of a classic strain of microalgae cells.

[0214] Implementation scheme [2]. The oil described in implementation scheme [1], wherein the fatty acid content of the TAG component contains at least 35% C16:0 fatty acids.

[0215] Implementation scheme [3]. The oil described in implementation scheme [1], wherein the fatty acid content of the TAG component contains at least 40% C16:0 fatty acids.

[0216] Implementation scheme [4]. The oils and fats described in any one of Implementation schemes [1] to [3], wherein the fatty acid content of the TAG component further comprises less than 8% C18:2 fatty acids.

[0217] Implementation scheme [5]. The oils described in any one of Implementation schemes [1] to [4], wherein the microalgae cells belong to the non-green algae genus.

[0218] Implementation Scheme [6]. The oil or fat described in any one of Implementation Schemes [1] to [5], wherein the fatty acid content of the TAG component comprises at least 45% C18:1 fatty acids.

[0219] Implementation scheme [7]. The oils and fats described in any one of Implementation schemes [1] to [6] further contain less than 1% monoacylglycerol (MAG).

[0220] Implementation scheme [8]. The oils and fats described in any one of Implementation schemes [1] to [7] further contain less than 1% diacylglycerol (DAG).

[0221] The oils and fats described in any one of the embodiments [1] to [8] further contain less than 1% tripalmitic acid glyceride.

[0222] Implementation scheme

[10] . Oils and fats according to any one of implementation schemes [1] to [9], wherein the oils and fats contain ergosterol.

[0223] Implementation Scheme

[11] . An unpurified oil derived from a non-green algae microalgae cell strain obtained by modification of a classic strain, wherein the unpurified oil contains a triacylglycerol (TAG) component, wherein the TAG component has a fatty acid content of 30% or more of C16:0 fatty acids and less than 1% of tripalmitoylglycerol esters.

[0224] Implementation scheme

[12] . The oil described in implementation scheme

[11] , wherein the oil is produced from a modified strain of a classic microalgae cell.

[0225] Implementation scheme

[13] . The oils and fats described in any one of Implementation schemes

[10] to

[12] , wherein the fatty acid content of the TAG component further comprises at least 40% C18:1 fatty acids.

[0226] Implementation scheme

[14] . Oils and fats according to any one of implementation schemes

[10] to

[13] , wherein the oils and fats further contain ergosterol.

[0227] Implementation scheme

[15] . Oils according to any one of implementation schemes

[10] to

[14] , wherein the microalgal cells do not contain exogenous genes.

[0228] The oils and fats described in any one of embodiments

[10] to

[15] further contain less than 1% monoacylglycerol (MAG).

[0229] The oils and fats described in any one of embodiments

[10] to

[16] further contain less than 1% diacylglycerol (DAG).

[0230] Implementation Scheme

[18] . The oils and fats described in any one of Implementation Schemes

[10] to

[14] , wherein the fatty acid content of the TAG component further comprises less than 8% C18:2 fatty acids.

[0231] Implementation Scheme

[19] . An unpurified microalgal oil comprising: a triacylglycerol (TAG) component having a fatty acid content of at least 30% C16:0 fatty acids, less than about 1% diacylglycerols and less than about 1% monoacylglycerols.

[0232] The oil described in any one of the implementation schemes

[20] . The oil described in any one of the implementation schemes

[19] , wherein the oil is derived from non-green algae microalgae cells.

[0233] Implementation scheme

[21] . Oils or fats as described in any one of implementation schemes

[19] or

[20] , wherein the oils or fats are derived from oil-producing microorganisms.

[0234] Implementation scheme

[22] . Oils in any one of implementation schemes

[19] or

[21] , wherein the microalgal cells do not contain exogenous genes.

[0235] Implementation Scheme [1A]. An isolated microalgal cell, wherein the microalgal cell is a cell of a non-green algae species obtained by modification of classical microalgal cells, wherein the microalgal cell produces an oil, the oil being characterized in that it comprises: (a) The triacylglycerol (TAG) component contains at least 17% 1,3-dipalmitoyl-2-oleoylglycerol (POP), or at least 23%, or at least 29%, or at least 32%, or at least 35%, or at least 45%, and (b) The content of tripalmitoylglycerol (PPP) in the TAG component is less than 0.3%, or less than about 0.6%, or less than about 1.0%, or less than at least 1.2%, or less than about 1.5%, or less than about 2.7%.

[0236] Implementation scheme [2A]. The isolated microalgal cells described in implementation scheme [1A] have a POP content of at least 45% and a PPP content of less than about 2.7% of the TAG component.

[0237] Implementation scheme [3A]. The isolation of microalgal cells as described in implementation scheme [1A] or implementation scheme [2A], wherein the microalgal cell lipids comprise: (a) At least about 50% 1,3-dipalmitoyl-2-oleoylglycerol (POP), and (b) Less than about 2.7% of tripalmitoylglycerol (PPP) in the TAG component.

[0238] Implementation Scheme [4A]. A microalgal oil comprising a triacylglycerol (TAG) component, wherein the TAG component comprises: (a) at least 17% of 1,3-dipalmitoyl-2-oleoylglycerol (POP) content of the TAG component, or at least 23%, or at least 29%, or at least 32%, or at least 35%, or at least 45% of the TAG component, (b) less than 0.3% of tripalmitoylglycerol (PPP) content of the TAG component, or less than about 0.6%, or less than about 1.0%, or less than at least 1.2%, or less than about 1.5%, or less than about 2.7% of the TAG component, and wherein the microalgal oil is produced by microalgal cells of the genus *Aureobasidium* obtained through modification of classical strains.

[0239] Implementation Scheme [5A] The microalgal oil of any one of Implementation Schemes [4A] to [5A], or the microalgal oil produced from isolated microalgal cells of any one of Implementation Schemes [1A] to [3A], wherein the non-green algae species cells have recombinantly introduced exogenous nucleic acids.

[0240] Implementation Scheme [6A]. The microalgal oil of any one of Implementation Schemes [4A] and [5A], wherein the TAG component comprises: (a) at least 45%, or at least 50%, or at least 55%, or at least 60% of 1,3-dipalmitoyl-2-oleoylglycerol (POP), and (b) less than about 2.7% of tripalmitoylglycerol (PPP) in the TAG.

[0241] Implementation scheme [7A]. The microalgal oil of implementation scheme [5A], wherein the microalgal oil has (a) a POP content of at least 35% and a PPP content of less than about 1.5%, or (b) a POP content of at least 45% and a PPP content of less than about 2.7%.

[0242] Implementation Scheme [8A]. The microalgal oil of any one of Implementation Schemes [4A] to [7A], wherein the oil further comprises at least about 30% of C16:0 fatty acids, or at least about 35% of C16:0 fatty acids, or at least about 40% of C16:0 fatty acids, or at least about 45% of C16:0 fatty acids, or at least about 50% of C16:0 fatty acids.

[0243] Implementation Scheme [9A]. A method for obtaining microalgal cells capable of producing the lipids described in any one of Implementation Schemes [4A] to [8A], the method comprising the following steps: (a) While culturing microalgal cells in a nutrient medium or lipid-producing medium at about 28°C to about 38°C, the microalgal cells are mutagenized with at least one or more known active agents that promote DNA excision repair errors (e.g., ultraviolet light (e.g., 254 nm), 4-nitroquinoline-1-oxide (4-NQO), methyl methanesulfonate (MMS), Ni, Ar or polycyclic aromatic hydrocarbons). (b) The mutagenized microalgal cells are enriched by exposing them to physical conditions (e.g., elevated temperatures of about 50 to about 68°C, or by density fractionation according to sucrose or Percoll gradient to separate specific subpopulations according to density) or to chemical compounds (e.g., herbicides, fungicides or lipid biosynthesis inhibitors such as chlorpyrifos or chlorpyrifos). (c) Growth of mutagenized and enriched microalgal cells in lipid-producing medium; (d) Microalgal lipids were harvested from the microalgal cells and analyzed using FAME and TAG analysis to determine the composition of the screened microalgal cells; and The TAG components of the screened microalgal cells include: (i) The TAG component contains at least 17% 1,3-dipalmitoyl-2-oleoylglycerol (POP), or at least 23%, or at least 29%, or at least 32%, or at least 35%, or at least 45%, and (ii) The content of tripalmitoylglycerol (PPP) in the TAG component is less than 0.3%, or less than about 0.6%, or less than about 1.0%, or less than at least 1.2%, or less than about 1.5%, or less than about 2.7%.

[0244] Implementation scheme [10A]. The method described in implementation scheme [9A], wherein the microalgal cells are mulberry-shaped non-green algae.

[0245] Implementation scheme [11A]. An isolated microalgal cell obtained by the method described in implementation schemes [9A] to [10A].

[0246] Implementation Scheme [12A]. The microalgal cells described in Implementation Schemes [10A] to [11A], wherein the lipids of the microalgal cells further comprise at least about 30% of C16:0 fatty acids, or at least about 35% of C16:0 fatty acids, or at least about 40% of C16:0 fatty acids, or at least about 45% of C16:0 fatty acids, or at least about 50% of C16:0 fatty acids.

[0247] Implementation Scheme [13A]. A method for obtaining microalgal oil according to any one of Implementation Schemes [1A] to [3A], comprising the following steps: (a) Mutagenesis of cells with an active agent known to induce mutations by promoting DNA excision repair errors; said active agent including but not limited to ultraviolet light (254 nm), 4-nitroquinoline-1-oxide (4-NQO), methyl methanesulfonate (MMS), Ni, Ar or polycyclic aromatic hydrocarbons; said microalgal cells cultured for a sufficient time in a nutrient medium or lipid-producing medium at about 28°C to about 38°C. (b) Enrich the cell population using physical conditions (e.g., elevated temperatures of about 50°C, about 60°C, or up to about 68°C, or fractionation according to a sucrose or Percoll gradient to separate specific subpopulations according to density) or exposure to chemical compounds (e.g., herbicides, fungicides, or lipid biosynthesis inhibitors such as chlorpyrifos or chlorpyrifos). (c) Spread the mutagenized and enriched cell population onto a solid nutrient medium; (d) Selecting and growing clones selected from coated cells in lipid-producing medium; (e) Harvesting microalgal cells from the lipid-producing medium; and (f) Using FAME analysis, obtain and detect microalgal lipids from selected cells and determine whether the selected cells have at least 17% of 1,3-dipalmitoyl-2-oleoylglycerol (POP) content of TAG components, or at least 23%, or at least 29%, or at least 32%, or at least 35%, or at least 45%; and less than 0.3%, or less than about 0.6%, or less than about 1.0%, or less than at least 1.2%, or less than about 1.5%, or less than about 2.7% of tripalmitoylglycerol (PPP) content of TAG components.

[0248] Implementation Scheme [14A]. An isolated microalgal cell, wherein the microalgal cell is a non-green algae species that produces microalgal lipids, the lipids being characterized by comprising: (a) At least 60% 1,3-dipalmitoyl-2-oleoylglycerol (POP) content, and (b) The triacylglycerol (TAG) component is less than about 2% of the tripalmitoylglycerol (PPP) content, and the non-chlorophyll species that produce the microalgal oil are obtained by modifying the classical microalgal cells of isolated non-chlorophyll species.

[0249] Implementation Scheme [15A]. A microalgal oil comprising a triacylglycerol (TAG) component, wherein the TAG component comprises: (a) The TAG component contains at least 60% 1,3-dipalmitoyl-2-oleoylglycerol (POP), and (b) The TAG component contains less than about 2% tripalmitoylglycerol (PPP) content, and The microalgal oils mentioned therein are produced by cells of microalgae species that are modified from classical microalgae strains of isolated non-green algae species. Claims (as amended under Article 19 of the Treaty) 1. An isolated microalgal cell, wherein the microalgal cell is a non-green algae species obtained through modification of classical microalgal cells ( ). Prototheca sp .) cells, wherein the microalgal cells produce an oil, the oil being characterized by comprising: (a) A content of at least 17% of 1,3-dipalmitoyl-2-oleoylglycerol (POP) in the triacylglycerol (TAG) component, or at least 23%, or at least 29%, or at least 32%, or at least 35%, or at least 45% of the TAG component, and (b) The content of tripalmitoylglycerol (PPP) in the TAG component is less than 0.3%, or less than about 0.6%, or less than about 1.0%, or less than at least 1.2%, or less than about 1.5%, or less than about 2.7%. 2. The isolated microalgal cells of claim 1, wherein the POP content is at least 45% and the PPP content is less than about 2.7% of the TAG component. 3. The isolated microalgal cells according to claim 1 or claim 2, wherein the microalgal cell lipids comprise: (a) At least 50% 1,3-dipalmitoyl-2-oleoylglycerol (POP) content, and (b) Less than about 2.7% of tripalmitoylglycerol (PPP) in the TAG component. 4. A microalgal oil comprising a triacylglycerol (TAG) component, wherein the triacylglycerol (TAG) component comprises: (a) The TAG component contains at least 17% 1,3-dipalmitoyl-2-oleoylglycerol (POP), or at least 23%, 29%, 32%, 35%, or 45% of the TAG component. (b) The content of tripalmitoylglycerol (PPP) in the TAG component is less than 0.3%, or less than about 0.6%, or less than about 1.0%, or less than at least 1.2%, or less than about 1.5%, or less than about 2.7%, and The microalgal oils mentioned therein are produced by cells of a non-green algae species obtained through the modification of classic strains. 5. The microalgal oil of claim 4, or the microalgal oil produced from isolated microalgal cells of any one of claims 1 to 3, wherein the non-green algae cells have recombinantly introduced exogenous nucleic acids. 6. The microalgal oil of claim 4 or claim 5, or the microalgal oil of isolated microalgal cells of any one of claims 1 to 3, wherein the TAG component comprises: (a) The TAG component contains at least 45% 1,3-dipalmitoyl-2-oleoylglycerol (POP), and (b) The content of tripalmitoylglycerol (PPP) in the TAG component is less than about 2.7%. 7. The microalgal oil of claim 5, wherein the microalgal oil has (a) a POP content of at least 35% and a PPP content of less than about 1.5%, or (b) a POP content of at least 45% and a PPP content of less than about 2.7%. 8. The microalgae oil of any one of claims 4 to 7, wherein the oil comprises at least about 30% C16:0 fatty acids, or at least about 35% C16:0 fatty acids, or at least about 40% C16:0 fatty acids, or at least about 45% C16:0 fatty acids, or at least about 50% C16:0 fatty acids. 9. A method for obtaining microalgal cells capable of producing microalgal lipids as defined in any one of claims 4 to 8, the method comprising the following steps: (a) While culturing microalgal cells in a nutrient medium or lipid-producing medium at about 28°C to about 38°C, the microalgal cells are mutagenized with at least one or more known active agents that promote DNA excision repair errors (e.g., ultraviolet light (e.g., 254 nm), 4-nitroquinoline-1-oxide (4-NQO), methyl methanesulfonate (MMS), Ni, Ar or polycyclic aromatic hydrocarbons). (b) The mutagenized microalgal cells are enriched by exposing them to physical conditions (e.g., elevated temperatures of about 50 to about 68°C, or by density fractionation according to sucrose or Percoll gradient to separate specific subpopulations according to density) or chemical compounds (e.g., herbicides, fungicides or lipid biosynthesis inhibitors such as chlorpyrifos or chlorpyrifos). (c) Growth of mutagenized and enriched microalgal cells in lipid-producing medium; (d) Microalgal lipids were harvested from the microalgal cells and detected using FAME analysis and triglyceride (TAG) analysis to determine the composition of the screened microalgal cells; The TAG components of the screened microalgal cells include: (i) The TAG component contains at least 17% 1,3-dipalmitoyl-2-oleoylglycerol (POP), or at least 23%, or at least 29%, or at least 32%, or at least 35%, or at least 45%, and (ii) The content of tripalmitoylglycerol (PPP) in the TAG component is less than 0.3%, or less than about 0.6%, or less than about 1.0%, or less than at least 1.2%, or less than about 1.5%, or less than about 2.7%. 10. The method of claim 9, wherein the microalgae cells are non-green algae species. 11. An isolated microalgal cell obtained by the method of claim 9 or 10. 12. A microalgal oil obtained from microalgal cells according to any one of claims 1 to 3 and 10, wherein the oil from the microalgal cells further comprises at least about 30% C16:0 fatty acids, or at least about 35% C16:0 fatty acids, or at least about 40% C16:0 fatty acids, or at least about 45% C16:0 fatty acids, or at least about 50% C16:0 fatty acids. 13. A method for obtaining microalgal cells capable of producing microalgal lipids according to any one of claims 1 to 3, the method comprising the following steps: (a) Mutagenesis of cells using an active agent known to induce mutations by promoting DNA excision repair errors; said active agent including, but not limited to, ultraviolet light (254 nm), 4-nitroquinoline-1-oxide (4-NQO), methyl methanesulfonate (MMS), Ni, Ar, or polycyclic aromatic hydrocarbons; and culture said microalgal cells in a nutrient medium or lipid-producing medium at about 28°C to about 38°C. (b) Enrich the cell population using physical conditions (e.g., elevated temperatures of about 50°C, about 60°C, or up to about 68°C, or fractionation according to a sucrose or Percoll gradient to separate specific subpopulations according to density) or chemical compounds (e.g., herbicides, fungicides, or lipid biosynthesis inhibitors such as chlorpyrifos or chlorpyrifos). (c) The mutagenized and enriched cell population was spread onto a solid nutrient medium; (d) Growing clones selected from coated cells in lipid-producing medium; (e) Harvesting microalgal cells from the lipid-producing medium; and (f) Microalgal lipids were obtained and characterized from selected cells using FAME and TAG analyses, and it was determined whether the selected cells contained at least 17% of 1,3-dipalmitoyl-2-oleoylglycerol (POP) of the TAG component, or at least 23%, or at least 29%, or at least 32%, or at least 35%, or at least 45%; and less than 0.3%, or less than about 0.6%, or less than about 1.0%, or less than at least 1.2%, or less than about 1.5%, or less than about 2.7% of the tripalmitoylglycerol (PPP) of the TAG component. 14. A biomass obtained from cultured microalgal cells according to any one of claims 1-3, wherein the biomass is optionally washed and / or dried.

Claims

1. An isolated microalgal cell, wherein the microalgal cell is a non-green algae species obtained through modification of classical microalgal cells ( ). Prototheca sp .) cells, wherein the microalgal cells produce an oil, the oil being characterized by comprising: (a) A content of at least 17% of 1,3-dipalmitoyl-2-oleoylglycerol (POP) in the triacylglycerol (TAG) component, or at least 23%, or at least 29%, or at least 32%, or at least 35%, or at least 45% of the TAG component, and (b) The content of tripalmitoylglycerol (PPP) in the TAG component is less than 0.3%, or less than about 0.6%, or less than about 1.0%, or less than at least 1.2%, or less than about 1.5%, or less than about 2.7%.

2. The isolated microalgal cells of claim 1, wherein the POP content is at least 45% and the PPP content is less than about 2.7% of the TAG component.

3. The isolated microalgal cells according to claim 1 or claim 2, wherein the microalgal cell lipids comprise: (a) At least 50% 1,3-dipalmitoyl-2-oleoylglycerol (POP) content, and (b) Less than about 2.7% of tripalmitoylglycerol (PPP) in the TAG component.

4. A microalgal oil comprising a triacylglycerol (TAG) component, wherein the triacylglycerol (TAG) component comprises: (a) The TAG component contains at least 17% 1,3-dipalmitoyl-2-oleoylglycerol (POP), or at least 23%, 29%, 32%, 35%, or 45% of the TAG component. (b) The content of tripalmitoylglycerol (PPP) in the TAG component is less than 0.3%, or less than about 0.6%, or less than about 1.0%, or less than at least 1.2%, or less than about 1.5%, or less than about 2.7%, and The microalgal oils mentioned therein are produced by cells of a non-green algae species obtained through the modification of classic strains.

5. The microalgal oil of claim 4, or the microalgal oil produced from isolated microalgal cells of any one of claims 1 to 3, wherein the non-green algae cells have recombinantly introduced exogenous nucleic acids.

6. The microalgal oil of claim 4 or claim 5, or the microalgal oil of isolated microalgal cells of any one of claims 1 to 3, wherein the TAG component comprises: (a) The TAG component contains at least 45% 1,3-dipalmitoyl-2-oleoylglycerol (POP), and (b) The content of tripalmitoylglycerol (PPP) in the TAG component is less than about 2.7%.

7. The microalgal oil of claim 5, wherein the microalgal oil has (a) a POP content of at least 35% and a PPP content of less than about 1.5%, or (b) a POP content of at least 45% and a PPP content of less than about 2.7%.

8. The microalgae oil of any one of claims 4 to 7, wherein the oil comprises at least about 30% C16:0 fatty acids, or at least about 35% C16:0 fatty acids, or at least about 40% C16:0 fatty acids, or at least about 45% C16:0 fatty acids, or at least about 50% C16:0 fatty acids.

9. A method for obtaining microalgal cells capable of producing microalgal lipids as defined in any one of claims 4 to 8, the method comprising the following steps: (a) While culturing microalgal cells in a nutrient medium or lipid-producing medium at about 28°C to about 38°C, the microalgal cells are mutagenized with at least one or more known active agents that promote DNA excision repair errors (e.g., ultraviolet light (e.g., 254 nm), 4-nitroquinoline-1-oxide (4-NQO), methyl methanesulfonate (MMS), Ni, Ar or polycyclic aromatic hydrocarbons). (b) The mutagenized microalgal cells are enriched by exposing them to physical conditions (e.g., elevated temperatures of about 50 to about 68°C, or by density fractionation according to sucrose or Percoll gradient to separate specific subpopulations according to density) or chemical compounds (e.g., herbicides, fungicides or lipid biosynthesis inhibitors such as chlorpyrifos or chlorpyrifos). (c) Growth of mutagenized and enriched microalgal cells in lipid-producing medium; (d) Microalgal lipids were harvested from the microalgal cells and detected using FAME analysis and triglyceride (TAG) analysis to determine the composition of the screened microalgal cells; The TAG components of the screened microalgal cells include: (i) The TAG component contains at least 17% 1,3-dipalmitoyl-2-oleoylglycerol (POP), or at least 23%, or at least 29%, or at least 32%, or at least 35%, or at least 45%, and (ii) The content of tripalmitoylglycerol (PPP) in the TAG component is less than 0.3%, or less than about 0.6%, or less than about 1.0%, or less than at least 1.2%, or less than about 1.5%, or less than about 2.7%.

10. The method of claim 9, wherein the microalgae cells are non-green algae species.

11. An isolated microalgal cell obtained by the method of claim 9 or 10.

12. A microalgal oil obtained from microalgal cells according to any one of claims 1 to 3 and 10, wherein the oil from the microalgal cells further comprises at least about 30% C16:0 fatty acids, or at least about 35% C16:0 fatty acids, or at least about 40% C16:0 fatty acids, or at least about 45% C16:0 fatty acids, or at least about 50% C16:0 fatty acids.

13. A method for obtaining microalgal cells capable of producing microalgal lipids according to any one of claims 1 to 3, the method comprising the following steps: (a) Mutagenesis of cells using an active agent known to induce mutations by promoting DNA excision repair errors; said active agent including, but not limited to, ultraviolet light (254 nm), 4-nitroquinoline-1-oxide (4-NQO), methyl methanesulfonate (MMS), Ni, Ar, or polycyclic aromatic hydrocarbons; and culture said microalgal cells in a nutrient medium or lipid-producing medium at about 28°C to about 38°C. (b) Enrich the cell population using physical conditions (e.g., elevated temperatures of about 50°C, about 60°C, or up to about 68°C, or fractionation according to a sucrose or Percoll gradient to separate specific subpopulations according to density) or chemical compounds (e.g., herbicides, fungicides, or lipid biosynthesis inhibitors such as chlorpyrifos or chlorpyrifos). (c) The mutagenized and enriched cell population was spread onto a solid nutrient medium; (d) Growing clones selected from coated cells in lipid-producing medium; (e) Harvesting microalgal cells from the lipid-producing medium; and (f) Microalgal lipids were obtained and characterized from selected cells using FAME and TAG analyses, and it was determined whether the selected cells contained at least 17% of 1,3-dipalmitoyl-2-oleoylglycerol (POP) of the TAG component, or at least 23%, or at least 29%, or at least 32%, or at least 35%, or at least 45%; and less than 0.3%, or less than about 0.6%, or less than about 1.0%, or less than at least 1.2%, or less than about 1.5%, or less than about 2.7% of the tripalmitoylglycerol (PPP) of the TAG component.